

Finnish Red Cross Blood Service
and Faculty of Biological and Environmental Sciences,
Department of Biosciences,
University of Helsinki,
Finland

**THE ESTABLISHMENT OF EFFICIENT
METHODS TO CULTURE
IMMUNOSUPPRESSIVE MESENCHYMAL
STROMAL CELLS FROM CORD BLOOD AND
BONE MARROW**

Anita Laitinen

ACADEMIC DISSERTATION

To be presented for public examination with the permission of the Faculty of
Biological and Environmental sciences of
the University of Helsinki, in Nevanlinna Auditorium of the Finnish Red Cross Blood
Service, Kivihaantie 7, Helsinki,
on August 26th, 2016 at 12 noon.

Helsinki 2016

ACADEMIC DISSERTATION FROM THE FINNISH RED CROSS BLOOD
SERVICE NUMBER 60

- Supervisors: Saara Laitinen, PhD
Finnish Red Cross Blood Service
Helsinki, Finland
- Adj. prof. Johanna Nystedt, PhD
Finnish Red Cross Blood Service
Helsinki, Finland
- Thesis committee: Adj. prof. Pia Siljander, PhD
Department of Biosciences, University of Helsinki
Helsinki, Finland
- Adj. prof. Esko Kankuri, MD
Medicum, University of Helsinki
Helsinki, Finland
- Reviewers: Professor Wolfgang Wagner, MD, PhD
Helmholtz Institute for Biomedical Engineering, Aachen
University
Aachen, Germany
- Lorenza Lazzari, PhD
Cell Factory, Unit of Cell Therapy and Cryobiology
Fondazione IRCCS Ca' Granda Ospedale Maggiore
Policlinico
Milan, Italy
- Opponent: Adj. prof. Susanna Miettinen
Adult Stem Cells, BioMediTech, University of Tampere
Tampere, Finland
- Custos: Professor Juha Voipio, PhD
Department of Biosciences, University of Helsinki
Helsinki, Finland

ISBN 978-952-5457-39-1 (print)

ISBN 978-952-5457-40-7 (pdf)

ISSN 1236-0341

<http://ethesis.helsinki.fi>

Helsinki 2016

Unigrafia

CONTENTS

List of original publications	6
Abstract.....	8
Abbreviations	10
1 Review of the literature	12
1.1 Cell Therapies	12
1.1.1 Cell types in cell therapies	13
1.2 Mesenchymal Stromal Cells	16
1.2.1 Functional mechanisms of MSCs	19
1.2.1.1 Tissue repair by cell replacement and differentiation	19
1.2.1.2 Secreted soluble factors	20
1.2.2 Tissue sources	26
1.2.3 Clinical use of MSCs and clinical trials.....	27
1.3 Culture of MSCs	30
1.3.1 Culture media.....	31
1.3.1.1 FBS and its substitutes	32
1.3.2 Oxygen concentration	34
1.3.3 Culture of MSCs for clinical use.....	36
1.3.3.1 Regulation and good manufacturing practice (GMP)	36
2 Aims of the study	39
3 Materials and methods	40
3.1 Ethics.....	40
3.2 Methods	40

3.2.1	Different culture media.....	42
4	Results.....	43
4.1	An efficient method to culture MSCs from CB.....	43
4.1.1	The success rate of obtaining MSCs from CB.....	43
4.1.2	The impact of culture conditions on the proliferation of CB- MSCs	43
4.2	Development of culture method for clinical-grade BM-MSCs.....	45
4.2.1	Development of PL supplements.....	45
4.2.2	The impact of culture conditions on BM-MSC proliferation	46
4.3	Characteristics of MSCs and the impact of culture conditions	48
4.3.1	Phenotype.....	48
4.3.2	<i>HOX</i> fingerprint.....	48
4.3.3	Differentiation potential	49
4.4	The impact of culture conditions on MSC functionality	50
4.4.1	The capacity of MSCs to support angiogenesis	50
4.4.2	The capacity of MSCs to suppress T cell proliferation	50
4.5	Adenosine production, one of the immunosuppressive mechanisms of MSCs	51
4.5.1	Expression of CD73 and CD39.....	51
4.5.2	The production of Adenosine.....	52
4.5.3	The effect of adenosine in an immunosuppression assay	52
5	Discussion	54
5.1	Establishment of efficient and robust culture conditions for CB- and BM-MSCs	54
5.2	Impact of culture conditons on MSC characteristics and functionality	58

5.3	Adenosine production as an immunosuppressive mechanism of MSCs	60
5.4	Concluding remarks and future perspectives.....	62
	Acknowledgements	63
	References	65

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following publications:

- I. Laitinen A, Nystedt J, Laitinen S. The isolation and culture of human cord blood-derived mesenchymal stem cells under low oxygen conditions. *Methods Mol Biol.* 2011;698:63-73
- II. Laitinen A, Lampinen M, Liedtke S, Kilpinen L, Kerkelä E, Sarkanen JR, Heinonen T, Kogler G, Laitinen S. The effects of culture conditions on the functionality of efficiently obtained mesenchymal stromal cells from human cord blood. *Cytotherapy.* 2016 Mar;18(3):423-37
- III. Laitinen A, Oja S, Kilpinen L, Kaartinen T, Möller J, Laitinen S, Korhonen M, Nystedt J. A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells. *Cytotechnology* 2015 Mar 17. (Epub ahead of print)
- IV. Kerkelä E, Laitinen A, Rabinä J, Valkonen S, Takatalo M, Larjo A, Veijola J, Lampinen M, Siljander P, Lehenkari P, Alfthan K, Laitinen S. Adenosinergic immunosuppression by human mesenchymal stromal cells requires co-operation with T cells. *Stem Cells.* 2016 Mar;34(3):781-90

The publications are referred to in the text by their roman numerals.

The original publications are reproduced with permission of their copyright holders.

Author contribution

Anita Laitinen (AL) is fully responsible for the summary of this doctoral thesis. AL was the main author in publications I, II and III. In publication **I**, AL designed the work and established the culture method. In publication **II**, AL established the cell culture method, designed, performed and analyzed the comparative long term cell culture studies. AL performed and analyzed the immunophenotypic characterization and differentiation assays. AL also participated in the design of the angiogenesis study and designed and participated in the performance and analysis of the T cell proliferation assays. In publication **III**, AL participated in the study design and performed and analyzed the comparative short term cell culture studies presented. AL also designed, performed and analyzed most of the T cell proliferation assays and participated in the phenotypic characterizations and differentiation assays. In publication

IV, AL participated in the conception and design of the study. AL participated in the design, performance and analysis of the phenotypic characterization of the cells. AL participated in the design of nucleotide measurements and in the design, performance and analysis of T cell proliferation assays. AL also participated in the manuscript writing.

ABSTRACT

Advanced cell therapies are evolving at an enormous pace. Mesenchymal stromal cells (MSCs) have become the focus of cell based therapies due to their capacity to home to the site of infection or tissue damage, to suppress immune reactions, and to support the regeneration of tissues. Bone marrow (BM) is a rich source of MSCs but other sources, such as cord blood (CB), have been presented as an attractive alternative because of the ease of access and abundance of this material. A good culture method constitutes the basis for clinical production of MSCs. The traditional cell culture method of BM-derived MSCs (BM-MSCs) is not an efficient technique for obtaining MSCs from CB. Thus, the development of cell culture methods is necessary for this material to be utilized in MSC research and therapy. Even small changes in the environment of MSCs may alter the phenotype or functional capacity of these cells. The knowledge of the functional capacities of MSCs and conditions that impact them will help in production of specific MSCs for various indications.

The aim of this thesis was to establish a culture condition for efficient production of MSCs from human CB and to compare different good manufacturing practice (GMP)-compliant methods to establish a robust method to culture human BM-MSCs in platelet lysate (PL)-containing culture medium. The impact of culture conditions, both culture media and oxygen (O₂) concentration, on the characteristics and functionality of MSCs was studied. Another aim of this thesis was to gain knowledge about the immunosuppressive mechanisms of MSCs.

The culture method to obtain MSCs from human CB established in this thesis was efficient in obtaining MSCs from almost 90% of processed CB-units. This figure is much higher than presented previously in literature. As a result of the comparison of two different GMP-compliant culture methods for obtaining adequate numbers of BM-MSCs, we identified a robust method to culture MSCs for clinical purposes. The results from culturing MSCs in different O₂ concentrations indicated that low O₂ concentrations are beneficial for the MSC proliferation at late passages but this supportive impact is minimal at early passages. Culturing the cells in different media was demonstrated to impact the phenotype and functional capacities of MSCs. The expression of cell surface markers CD90 and HLA-DR was altered by different culture media. The functional capacities of MSCs were also influenced by different culture media. CB-MSCs cultured in medium without dexamethasone (DX) and containing only small amounts of growth factors showed a higher capacity to support angiogenesis than MSCs cultured in the presence of DX and in growth factor-rich medium. On the other hand, MSCs cultured in the presence of DX and

growth factor-rich medium were more efficient in suppressing T cell proliferation.

In this thesis, a novel mechanism for human MSCs and MSC-derived extracellular vesicles (MSC-EVs) to suppress T cell proliferation via adenosine (Ado) production was demonstrated. Ado was efficiently produced from ATP by the action of CD73 molecule on MSCs in concert with CD39 expressing T cells.

In conclusion, this thesis presents an efficient method for obtaining MSCs from CB and a GMP-compliant method for culturing BM-MSCs for clinical use. The culture medium and O₂ concentration have an effect on the proliferative potential, surface characteristics and functionality of MSCs, and they should be carefully studied when altering the culture protocols. This thesis also presents a novel immunomodulatory mechanism of MSCs, mediated by the activity of cell surface molecule CD73.

ABBREVIATIONS

Ado	Adenosine
ADP	Adenosine diphosphate
AMP	Adenosine monophosphate
AT	Adipose tissue
AT-MSCs	Adipose tissue-derived mesenchymal stromal cells
ATMP	Advanced therapy medicinal products
ATP	Adenosine triphosphate
bFGF	Basic fibroblast growth factor
BM	Bone marrow
BM-MSCs	Bone marrow-derived mesenchymal stromal cells
CAT	Committee for Advanced Therapies, at EMA
CB	Cord blood
CB-MSCs	Cord blood-derived mesenchymal stromal cells
CD	Cluster of differentiation
CFU-F	Colony-forming unit –fibroblasts
CM	Conditioned medium
CO ₂	Carbon dioxide
DC	Dendritic cell
DX	Dexamethasone
EGF	Epidermal growth factor
EHNA	erythro-9-(2-hydroxy-3-nonyl)adenine, adenosine deaminase inhibitor
ELISA	Enzyme-linked immunosorbent assay
EMA	European Medicines Agency
ESC	Embryonic stem cell
EV	Extracellular vesicle
FBS	Fetal bovine serum
FN	Fibronectin
GMP	Good manufacturing practice
GVHD	Graft versus host disease
HLA	Human leucocyte antigen
HOX	Homeobox
HPLC	High-performance liquid chromatography
HSC	Hematopoietic stem cell
IDO	Idoleamine-2,3-oxygenase
IFN γ	Interferon gamma
IL	Interleukin
iPS cell	Induced pluripotent stem cell
ISCT	International Society for Cellular Therapy
M1	Medium 1
M2	Medium 2

M3	Medium 3
MAPC	Multi potent adult progenitor cell
MC	Mononuclear cell
MIAMI cells	Marrow-isolated adult multi-lineage inducible cells
MSC	Mesenchymal stromal/stem cell
MSC-EV	Mesenchymal stromal cell-derived extracellular vesicles
MV	Microvesicle
NK cell	Natural killer cell
O ₂	Oxygen
PBMC	Peripheral blood mononuclear cell
PD	Population doubling
PDGF-BB	Platelet derived growth factor-BB
PL	Platelet lysate
PRP	Platelet rich plasma
qRT-PCR	Quantitative real-time polymerase chain reaction
RT-PCR	Reverse transcription polymerase chain reaction
sCTMP	Somatic cell therapy medicinal product
StdM	Standard growth medium
TEP	Tissue-engineered product
TGF	Transforming growth factor
TLR	Toll like receptor
Treg	Regulatory T cell
UC	Umbilical cord
UC-MSCs	Umbilical cord-derived MSCs
USSC	Unrestricted somatic stem cells
VEGF	Vascular endothelial growth factor

1 REVIEW OF THE LITERATURE

1.1 CELL THERAPIES

Cell therapy is defined as the administration of live cells into a patient with the intention to replace, augment, or modify the function of patients' cells that are diseased, dysfunctional, or missing. Cell therapy is another therapeutic application to complement the traditional pharmaceuticals, biopharmaceuticals, and medical devices in treatment of patients (Mason et al. 2011). Cell therapies can be conducted using either autologous or allogenic cell products. In autologous cell therapy, the patient is treated with his or her own cells in contrast to allogenic cell therapy which requires the transplantation of cells from a donor to a patient (Buckler et al. 2016).

The field of cell therapies has grown enormously during last decades and it is still steadily expanding (see Figure 1). The worldwide stem cell therapy market is estimated to grow at a rate of 39.5% from 2015 to 2020 (Buckler et al. 2016). Once limited to blood and bone marrow (BM) transplantation and reproductive *in vitro* fertilization, the field of cell therapies has moved towards advanced cell therapies. Cell therapies cover a broad range of specialties and applications, divided in permanent and transient cell therapy categories. The permanent cell therapies include the replacement of damaged tissue with functional cells such as damaged cornea replaced with corneal epithelial stem cells. The transient cell therapies include therapies such as the immunomodulatory therapy provided by adult stem cells (Mason et al. 2011).




Figure 1 Number of cell therapy trials. (A) The total number of cell therapy trials from 2011 to 2015. The total number of cell therapy trials was 631 in 2015 according to Alliance for Regenerative Medicine. (B) The number of cell therapy trials by cell type from 2011 to 2014 modified from Bersenev 2015. Data from Bersenev 2015 (Bersenev 2015) and from Annual Data Report by Alliance for Regenerative Medicine (http://alliancerm.org/sites/default/files/ARM_Annual_Report_2015_Web_Version_FINAL.pdf). Abbreviations: MSC, mesenchymal stromal cells; BM-MC, bone marrow mononuclear cells; HSPC, hematopoietic stem/progenitor cells; ESC, embryonic stem cells; DC, dendritic cells; NK, natural killer cells.

1.1.1 CELL TYPES IN CELL THERAPIES

Embryonic stem cells

Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst stage of an embryo (Evans and Kaufman 1981; Thomson et al. 1998). These rapidly proliferating pluripotent cells can be propagated *in vitro* indefinitely in particular culture conditions. The characteristics of cultured ESCs include the expression of some pluripotent markers (NANOG, SOX2, OCT4, and KLF4) and the cells have active telomerase and alkaline

phosphatase enzymes. Undifferentiated ESCs form teratomas (tumors with differentiated structures of ectoderm, mesoderm, and endoderm origin) when injected into an immune-deficient mouse, indicating their capacity to differentiate towards all three embryonic germ layers. ESCs can also be induced to differentiate into a range of committed somatic cells. Finding appropriate culture conditions to achieve efficient cell differentiation is one of the active areas within the ESC field (Alvarez et al. 2012).

Although ESCs have properties that sound promising for regenerative medicine and tissue replacement after an injury or a disease, these cells have several disadvantages in cell therapies. These problems include ethical issues, teratoma formation, and immune reactions after transplantation (Jung 2009). However, some clinical trials have been conducted, the first being a treatment of patients with acute spinal cord injury by Geron corporation. Geron Corporation started a phase I trial in 2010, using ESC-derived oligodendrocytes and treated 4 of the 10 planned patients before stopping the trial for economic reasons (Scott and Magnus 2014). In addition, some other phase I trials with ESC-derived cells are ongoing for treating macular degeneration (Mead et al. 2015).

Induced pluripotent stem cells

In 2006, Takahashi and Yamanaka (Takahashi and Yamanaka 2006) described the creation of induced pluripotent stem (iPS) cells. These cells share similar characteristics with ESCs including self-renewal capacity and the capacity to differentiate into various cell types. These cells were initially generated from adult somatic cells by retroviral delivery of four transcription factors: Oct4, Sox2, Klf4, and cMyc (Takahashi and Yamanaka 2006). Since then, it has been demonstrated that most of these four factors can be substituted with different factors, though some key factors such as OCT4 cannot be omitted (Yamanaka and Blau 2010).

The use of virus vectors to create iPS cells may produce insertional mutations, thus resulting even in tumor genesis (Hyun et al. 2007). To overcome this, Yu et al. presented a vector and transgene free system to induce iPS (Yu et al. 2009). However, despite the recent progress in designing protocols that reduce the risk of viral integrations and oncogene expression in generation of iPS cells, there are still technical challenges in the production of these cells and safety concerns regarding their use in clinical applications which require solving before clinical use (Ji et al. 2016).

While iPS cells possess similar pluripotent potential as ESCs, they do not have the same ethical problems as ESCs as they are derived from adult cells. They hold great potential for regenerative medicine as patient specific iPS cells can be generated to overcome the immune rejection typical of ESCs. iPS cells can also be used to model human diseases and screen drug candidates *in vitro*. In 2013, a clinical trial for macular degeneration with autologous iPS was started by Japanese RIKEN Center for Developmental Biology. The trial

was halted one year later due to mutations in second product and regulatory changes. The company also changed their strategy, deciding to move forward with allogenic iPS cells (<http://stemcellassays.com/2015/09/first-ips-cell-clinical-trial-insights/>).

Adult stem / progenitor cells

Adult stem and progenitor cells, including tissue specific stem cells, are multipotent cells found in differentiated tissues. These cells have a self-renewal capacity and the capacity to differentiate into the specialized cell types of the tissue. In contrast to ESCs, the differentiation capacity of adult stem cells is often restricted to certain lineages. Progenitor cells are described to have a more limited differentiation and self-renewal capacity than adult stem cells. The primary role of adult stem and progenitor cells is to maintain and repair the tissue where they reside.

The best known adult stem cell type is the hematopoietic stem cells (HSCs), which reside in the BM and form all types of blood cells. HSCs are routinely used for therapeutic purposes as BM transplantations have been conducted for several decades (Storb 2003). Another adult stem cell or progenitor cell type, initially found in BM (Friedenstein et al. 1968), is mesenchymal stromal/stem cells (MSCs). They are multipotent adult cells found in virtually all tissues of the body (Crisan et al. 2008). These multipotent cells have been called by several names due to their unique characteristics noticed *in vitro*. Besides MSCs, these multipotent cells include unrestricted somatic stem cells (USSC), marrow-isolated adult multilineage inducible (MIAMI) cells, multi potent adult progenitor cells (MAPCs), and very small embryonic-like (VSEL) cells (D'Ippolito et al. 2004; Jiang et al. 2002; Kogler et al. 2004; Kucia et al. 2006). These cells have been demonstrated to have several unique features but it is still not clear if they are hierarchically related to each other and constitute overlapping populations of early-development stem cells or whether they are just a consequence of differential culture procedures (Suszynska et al. 2014).

Several adult cell based products are already on the market. Holoclar® (Holostem Advanced Therapies), a stem cell therapy product, was the first advanced therapy medicinal product (ATMP) containing adult stem cells approved in the European Union (EU). This product consists of patient derived limbal stem cells and is used for the treatment of limbal stem cell deficiency due to physical or chemical burns of eyes (<http://www.eurostemcell.org/story/europe-approves-holoclar-first-stem-cell-based-medicinal-product>). Another tissue specific product with market approval in Europe is ChondroCelect® (TiGenix), which contains autologous *in vitro* expanded chondrocytes for repair of cartilage defects of the knee (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000878/WC500026031.pdf).

Immune cells

Several immune cell types have potential for use in cell therapies. Widely studied cell types in this field include T cells, natural killer (NK) cells, and dendritic cells, with the main focus on malignant and infectious disease therapies.

In T cell therapies, T cells are cultured and/or engineered *ex vivo* and adoptively transferred into a patient, or T cells can be directly targeted by vaccination or biological compounds (Guo et al. 2015). T cell therapies include the use of pathogen specific T cells, tumor infiltrating leucocytes (TIL) (Rosenberg et al. 1988), cytotoxic T lymphocytes (CTL) against virus associated malignancies (Schuessler et al. 2014), and genetically engineered T cells such as chimeric antigen receptor (CAR) T cells (Gill et al. 2016). Pathogen-specific T cells include virus-specific T cells against viruses such as cytomegalovirus (CMV) (Einsele et al. 2002) and fungus-specific T cells (Deo and Gottlieb 2015). Donor lymphocyte infusion (DLI) is used to tackle a hematopoietic malignancy relapse after HSC transplantation (Chang and Huang 2013). Regulatory T cells (Treg) have also been used in clinic to reduce the incidence of graft versus host disease (GVHD) (Trzonkowski et al. 2009).

Besides T cells, also other immune cells have been found to be applicable in cell therapies. Early clinical and preclinical studies have indicated that NK cells have great potential for targeting tumor cells. Autologous and allogenic NK cells have been demonstrated to be safe and without toxic effects in several clinical studies aimed at targeting tumors. The major risk involved in the use of allogenic NK cells is the development of GVHD. Although NK cell therapies represent a promising therapy against cancer, clinical trials have not clearly demonstrated their benefits in patients with malignancies (Dahlberg et al. 2015).

Dendritic cells (DCs) have also been used as immunotherapeutic agents against tumors. DC vaccines have been used in several clinical trials in cancer patients and sipuleucel-T (Provenge®, Dendreon Corporation), a product approved by authorities has shown significant survival advantage in metastatic castration-resistant prostate cancer (Mantia-Smaldone and Chu 2013).

1.2 MESENCHYMAL STROMAL CELLS

Mesenchymal stromal cells (MSCs) have been studied since 1960s, pioneered by Friedenstein (Friedenstein et al. 1968). He managed to culture a plastic adherent fibroblastic cell type from BM, which he named colony-forming unit -fibroblasts (CFU-F) (Friedenstein et al. 1976). Since then, these cells have been studied worldwide, with several names given to them (Charbord 2010; Horwitz et al. 2005). In 1991, these cells were named mesenchymal stem cells (Caplan 1991). Later on, International Society for Cellular Therapy

(ISCT) recommended that they be named multipotent mesenchymal stromal cells, using the same acronym MSC (Horwitz et al. 2005). This name was recommended as these cells do not literally fulfill the criteria for a true stem cell. MSCs have not been demonstrated to be capable of producing a tissue *in vivo*. A true stem cell should have self-renewal capacity, the capacity to produce differentiated progeny, and, when transplanted, they should be capable of regenerating a tissue.

Since the initial finding of MSCs from BM, these cells have been derived from various sources (Erices et al. 2000; Gronthos et al. 2000; in 't Anker et al. 2004; Wang et al. 2004; Zuk et al. 2002). They can be found in nearly all adult tissues where they are mostly located in the perivascular areas (Crisan et al. 2008). Actually, these cells share similarities with pericytes and thus there is a theory that the *in vivo* niche of MSCs is the perivascular area and the cultured MSCs are descendants of periendothelial cells (Caplan 2008; da Silva Meirelles et al. 2008).

MSCs are a heterogeneous population of cells containing just a small proportion of cells with stem cell characteristics. MSCs are defined as having certain characteristics. The minimal criteria defined by the ISCT (Dominici et al. 2006) are that these cell should be positive for CD90, CD73, and CD105 and negative for hematopoietic lineage cell surface markers such as CD34, CD14, CD45, CD19, and HLA-DR (see Table 1). They ought to have the capacity to differentiate into adipocytes, chondrocytes, and osteoblasts and they must be plastic adherent. These criteria were established as markers for human BM-derived and fetal bovine serum (FBS) cultured MSCs and were set as a basis for additional characterization. Other markers commonly expressed on MSCs derived from different tissues are the molecules CD13, CD29, CD44, CD166, and HLA I (Hass et al. 2011; Lv et al. 2014), see Table 1.

Table 1. *Cell surface markers commonly identified in MSCs and their expression on other cell types.*

Cell surface protein	activity/function	expression on other cells	expression on MSCs
CD13	zinc metalloproteinase	fibroblasts, endothelial cells, granulocytes, monocytes and mast cells	+
CD14	receptor for endotoxin (LPS)	macrophages, monocytes, granulocytes, dendritic cells and B-cells	- *
CD19	signal transduction molecule	B cells and follicular dendritic cells	-*
CD29	cell adhesion molecule (integrin β -1)	fibroblasts, platelets, T cells, monocytes, granulocytes, mast cells, endothelial cells and myoepithelial cells	+
CD34	cell-cell adhesion factor	hematopoietic stem and progenitor cells	-*
CD44	involved in cell-cell interactions, cell adhesion and cell migration	on most mammalian cell types	+
CD45	tyrosine phosphatase	hematopoietic cells	-*
CD49e	integrin alpha 5 subunit (join with β -1 unit)	T cells, thymocytes, B cells, platelets, monocytes and neutrophils	+
CD73	5'-nucleotidase	T cells, B cells, follicular dendritic cells, epithelial cells and endothelial cells	+*
CD90	cell-cell and cell-matrix interactions	hematopoietic stem cells, neurons, fibroblasts, thymocytes, follicular dendritic cells, lymph node HEV endothelium	+*
CD105	regulatory component of TGF- β receptor	endothelial cells, activated monocytes and tissue macrophages, pre B cells	+*
CD166	adhesion molecule	neurons, activated T cells, activated monocytes, epithelium, fibroblasts	+
HLA-ABC	major histocompatibility complex class I	all nucleated cells and platelets	+
HLA-DR	major histocompatibility complex class II	B cells, T cells, monocytes, macrophages and NK cells	-*

* criteria according to ISCT

1.2.1 FUNCTIONAL MECHANISMS OF MSCs

Beside the tri-lineage differentiation capacity of the MSCs described above, these cells have been demonstrated to have several other capabilities. These capabilities include the diverse plasticity to differentiate, the capacity to support the growth and differentiation of stem and progenitor cells (especially HSCs), the immunosuppressive and the angiogenic supporting capacity of the cells and the anti-apoptotic effects on other cells (Bronckaers et al. 2014; da Silva Meirelles et al. 2009). The mechanisms behind MSCs' functioning in cell therapies can be divided into two categories: permanent cell replacement and soluble factor mediated mechanisms (see Figure 2).




Figure 2 Functional mechanisms of MSCs. MSCs have the capacity to differentiate into different cell types at least *in vitro*. This capacity has been employed in permanent cell replacement in tissue repair. The regenerative benefits of MSCs have been demonstrated to be mainly consequences of the secreted factors.

1.2.1.1 Tissue repair by cell replacement and differentiation

MSCs have been demonstrated to have the capacity to differentiate, at least *in vitro*, into mesodermal, endodermal and ectodermal lineages. Besides the osteogenic, chondrogenic, and adipogenic differentiation, mesodermal differentiation into skeletal muscle, tendon, myocardium, smooth muscle, and endothelium has been demonstrated (Dezawa et al. 2005; Kuo and Tuan 2008; Makino et al. 1999; Oswald et al. 2004; Ross et al. 2006). The ectodermal and endodermal differentiation into epithelial cells, neurons, and

hepatocytes has been shown to occur in certain conditions (Lee et al. 2004a; Spees et al. 2003; Woodbury et al. 2000). However, the non-mesodermal differentiation of the cells is controversial and it has not been demonstrated convincingly *in vivo* (Strioga et al. 2012). Some of the *in vivo* trans-differentiation observations on MSCs have been shown to be due to the fusion of the MSCs with the contacted cells, and not via differentiation of MSCs (Alvarez-Dolado et al. 2003). Thus, the *in vitro* differentiation potential of MSCs does not necessarily correlate with the *in vivo* differentiation potential of the cells.

Due to the *in vitro* differentiation capacity of MSCs, it was initially hypothesized that the differentiation capacity of MSCs would be the curative mechanism of these cells in tissue regeneration/engineering. It was envisioned that the transplanted cells would directly replace the damaged tissue. Later on, the regenerative benefits of MSCs have been demonstrated to be mainly a consequence of the paracrine mechanisms of MSCs, rather than a result of their differentiation (Bronckaers et al. 2014; Noiseux et al. 2006; Togel et al. 2005). In tissue engineering, such as in repair of extensive bone defects, MSCs have been successfully used when seeded into scaffolds yielding a 3D bioimplant (Quarto et al. 2001; Sandor et al. 2014). The soluble factors secreted by MSCs together with osteoconductive biomaterials have shown to synergistically favor the production of good constructs (Wolff et al. 2013).

1.2.1.2 Secreted soluble factors

Immunomodulation

The discovery of the immunosuppressive capacity of MSCs has provided a potential tool for down-regulating the unwanted immune reactions. As MSCs do not express cell surface MHC II molecules without stimulation and they do not express co-stimulatory molecules CD80, CD86, or CD40 (Tse et al. 2003), they are often said to be immune privileged. Nowadays it is, however, known that also MSCs are recognized by the host immune system and they may stimulate the immune cells (Ankrum et al. 2014). MSCs have been demonstrated to induce the proliferation of allogenic unstimulated lymphocytes (Karlsson et al. 2012; Le Blanc et al. 2003b) and the production of antibodies by B cells (Rasmusson et al. 2007; Traggiai et al. 2008). Allogenic MSCs have also been shown to cause a rejection of BM transplant if co-transplanted to sub-lethally irradiated mice. They can also induce a memory T cell response (Nauta et al. 2006). Thus, MSCs should be called “immune evasive”, rather than immune privileged (Ankrum et al. 2014).

MSCs are able to suppress many types of immune cells of the innate and adaptive immune system. The overall picture of how MSCs influence the immune system is not yet clear, but an enormous number of different possible factors and mechanisms functioning via both soluble and cell

contact-dependent interactions have been demonstrated to be responsible for the immune modulatory effects. Several of the factors are listed in table 2. Contact dependent mechanisms such as PD-1 – PD-L1/2, Jagged1-Notch1, and Fas-Fas-L interactions in T and B cells have also been implicated (Akiyama et al. 2012; Augello et al. 2005; Liotta et al. 2008)

MSCs may influence the activation, differentiation, proliferation, and the cytokine production of T cells, B cells, NK cells, DCs, and macrophages via diverse mechanisms. MSCs have been shown to influence the expression of co-stimulatory molecules on antigen presenting cells (Beyth et al. 2005). They have also been demonstrated to inhibit the degranulation of mast cells (Brown et al. 2011) and there are indications that they influence the apoptosis of immune cells (Glenn and Whartenby 2014). As MSCs promote the macrophage polarization into the immunosuppressive M2 subset (Cho et al. 2014; Francois et al. 2012; Kim and Hematti 2009), they influence the creation of anti-inflammatory milieu and thus also reduce the migration of inflammatory cells to the site of tissue damage.

The immunosuppressive effects of MSCs have mostly been studied with T cells (van den Akker et al. 2013). Studies have shown that the suppressive effect of MSCs on T cell proliferation is enhanced when MSCs are pre-exposed to effector cytokines such as interferon gamma (IFN γ), TNF α , and interleukin (IL)-1 β (Chang et al. 2006a; Le Blanc et al. 2003a; Ren et al. 2008). Besides their suppressive effect on the proliferation of T cells, MSCs also suppress the IFN γ production of T_{h1} cells and promote the secretion of IL-4 by T_{h2} cells, while also increasing the amount of regulatory Tregs (Aggarwal and Pittenger 2005; English et al. 2009).

MSCs have been reported to express several toll-like receptors (TLRs) (Delarosa et al. 2012; van den Akker et al. 2013) and the activation of these innate immune system associated receptors may contribute to the polarization of MSCs into an anti- or pro-inflammatory phenotype (Waterman et al. 2010). Although, as there are many conflicting results regarding the effects of TLRs (Munir and McGettrick 2015), more research will be necessary to clarify their role in MSC immunomodulation properties.

Extracellular nucleotides (such as ATP, ADP, UTP, and UDP) are mediators of intercellular communications in virtually all tissues and they are important factors in cell stress (Burnstock 2006). These nucleotides are degraded into nucleosides, such as adenosine (Ado). Ado is found in every tissue and organ and it regulates their function. It has an important role in a wide variety of biochemical processes such as energy transfer and it also acts as an inhibitor in presynaptic excitatory neurotransmitter release (Borea et al. 2016). Ado mediates cardioprotective, neuroprotective, vasodilatory, and angiogenic responses and it counteracts the inflammatory/stress signal triggered by adenosine triphosphate (ATP) (Scarfi 2014). Ado is either released directly by cells or generated by de-phosphorylation of adenine nucleotides. This de-phosphorylation is performed by two ectonucleotidases, CD39 and CD73 (Scarfi 2014). The CD39 CD73 mediated adenosinergic

pathway has been demonstrated to be an important machinery used by Tregs to inhibit T cell proliferation and cytokine secretion (Deaglio et al. 2007). Recently this pathway has also been shown to have a relevant function in MSCs, as demonstrated with mice MSCs (Sattler et al. 2011). Chen et al. demonstrated that human gingiva-derived MSCs suppress the proliferation of murine CD4+CD25- T cell proliferation via the CD39 CD73 pathway (Chen et al. 2013). Recently, Amarnath et al. demonstrated the Ado signalling to be responsible for the therapeutic effect in a xenogeneic mouse GVHD model (Amarnath et al. 2015). The role of MSCs' Ado pathway has also been indicated in autoimmune responses in experimental autoimmune uveitis model in mice (Chen et al. 2016). Also, *in vitro* studies showing that human MSCs impact the suppression of human T cell functions via the Ado pathway have been published (Chen et al. 2016; Lee et al. 2014; Saldanha-Araujo et al. 2011).

As there are many different mechanisms behind the immunomodulatory effects of MSCs, it is most probable that a combination of different pathways will provide the optimal effect in each certain situation.

Angiogenesis supporting effects

Angiogenesis means the formation of new blood vessels from the pre-existing vasculature. Angiogenesis is a fundamental physiological event in the development of an individual and in wound and fracture healing (Bronckaers et al. 2014). Angiogenesis is a tightly regulated process initiated only in response to specific stimuli such as inflammation and hypoxia. The induction of endothelial cells to start a new branch of blood vessel requires the liberation of pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and stromal derived factor-1 (SDF-1). Angiogenic factors are naturally released during the proteolytic breakdown of extracellular matrix (ECM) of the capillaries (Bronckaers et al. 2014). MSCs secrete numerous angiogenic factors (Table 2) including VEGF, bFGF, placental growth factor (PLGF), monocyte chemoattractant protein-1 (MCP-1), IL-6, and insulin like growth factor-1 (IGF-1) (da Silva Meirelles et al. 2009).

Studies have shown that various conditions and factors have an impact on the capacity of MSCs to secrete angiogenic factors. It has been demonstrated that the induction of MSCs with chemokines and growth factors, such as transforming growth factor (TGF)- α and angiotensin II, induce the MSCs to secrete several angiogenic factors. Additionally, the conditioned medium (CM) of the induced cells is more efficient in supporting angiogenesis than the CM of non-treated MSCs (De Luca et al. 2011; Liu et al. 2015). According to studies, the angiogenic supporting capacity of MSCs is also enhanced by hypoxic environment (Aranha et al. 2010; Chen et al. 2008). In addition, serum-deprivation has been shown to increase the capacity of MSCs to be angiogenic (Oskowitz et al. 2011).

Studies have shown MSCs to be involved in all steps of angiogenesis *in vitro*. They induce endothelial cell proliferation, migration, invasion, and tube formation, and they have also been indicated to protect endothelial cells from apoptosis (Bronckaers et al. 2014). The capacity of MSCs to stabilize the newly formed vessels in a manner similar to pericytes has supported the pericyte theory (Caplan and Correa 2011). Besides the secretion of angiogenic factors, MSCs have also been demonstrated to differentiate into endothelial cell-like cells at least *in vitro* (Oswald et al. 2004), and this differentiation can be induced by several treatments of MSCs (Bekhite et al. 2014).

Table 2. Soluble factors secreted by MSCs (non-comprehensive)

Factors in	Targets	References
immunomodulation		
Idoleamine-2,3-oxygenase (IDO)	T cells, macrophages, NK cells	(Francois et al. 2012; Meisel et al. 2004; Spaggiari et al. 2008)
prostaglandin E2 (PGE2)	macrophages, DC, T cells, Mast cells, NK cells	(Aggarwal and Pittenger 2005; Brown et al. 2011; Spaggiari et al. 2008)
IL-6	neutrophils, DC, macrophages	(Djouad et al. 2007; Raffaghello et al. 2008; Zhang et al. 2010)
GM-CSF	macrophages	(Zhang et al. 2010)
IL-10	T cells	(Qu et al. 2012)
TGF- β 1	Treg	(Patel et al. 2010)
Nitric oxide (especially in mice)	T cells	(Shi et al. 2011)
heme oxygenase-1	T cells	(Chabannes et al. 2007)
HLA-G5	T cells	(Selmani et al. 2009)
Galectin-3	T cells	(Sioud et al. 2010)
Adenosine (Ado)	T cells	(Saldanha-Araujo et al. 2011)
angiogenesis and growth support		
VEGF	endothelial cells	(Kinnaird et al. 2004; Rehman et al. 2004)
IGF-1	endothelial cells	(Togel et al. 2007)
bFGF	endothelial cells	(Kinnaird et al. 2004)
PLGF	induction of vessel formation	(Kinnaird et al. 2004)
IL-6	endothelial cells	(Zhang et al. 2013)
MCP-1	endothelial cells	(Boomsma and Geenen 2012)
SDF-1	hematopoietic stem/progenitor cells	(Van Overstraeten-Schlogel et al. 2006)
angiopoietin 1	endothelial cells	(Wu et al. 2007)
anti-apoptosis		
VEGF	endothelial cells	(Rehman et al. 2004; Togel et al. 2007)
HGF	endothelial cells	(Rehman et al. 2004; Togel et al. 2007)
IGF-1	endothelial cells	(Togel et al. 2007)
stanniocalcin 1	epithelial cells, fibroblasts	(Block et al. 2009)
TGF- β	endothelial cells, cardiomyocytes	(Rehman et al. 2004; Wang et al. 2009)
bFGF	endothelial cells	(Rehman et al. 2004)

Extracellular vesicles

Besides the secretion of soluble molecules such as immunomodulatory and angiogenic factors, MSC have been described to secrete extracellular vesicles (EVs), subtyped as microvesicles (MVs) and exosomes. MVs are generated by budding of the cell membrane and they are 50 nm - 1,000 nm in size. Exosomes, which were originally thought a by-product of cell turnover, are slightly smaller (40-100 nm) or of the same size. Exosomes are thought to be of endosomal origin and to have homogenous characteristics with defined biophysical and biochemical properties, e.g. the constitution of their lipid membrane is well characterized (Madrigal et al. 2014; Rani et al. 2015). The types of different vesicles are not clearly defined and thus the nomenclature of these vesicles is confusing and the same term can mean different things to different investigators. It has been suggested that while there is no consensus about the nomenclature, the preferred term for these vesicles would be EVs (Gould and Raposo 2013).

EVs can be collected from all types of body fluids and also from cell culture supernatants. EVs facilitate the communication between cells by transferring bioactive molecules and they are involved in normal physiological processes. Liberated EVs may be internalized by other cells via endocytosis or cell type specific phagocytosis. Extracellular signals, such as hypoxia and inflammation, have been demonstrated to regulate the protein packing into EVs and their release from MSCs (Rani et al. 2015). EVs may also have a role in the development and progress of diseases. EVs have been linked to tumorigenesis, spread of viruses and pathogenic agents. In addition, factors involved in neurodegenerative diseases have been associated with EVs (Iraci et al. 2016).

The advantageous effect of MSC-derived EVs (MSC-EV) on several diseases has been demonstrated in several animal models. There is also evidence from animal models that points to their beneficial role in cutaneous wound healing and in the healing of myocardial infraction, acute kidney injury (AKI), liver diseases, and lung diseases (Arslan et al. 2013; Bruno et al. 2009; Kilpinen et al. 2013; Li et al. 2013; Timmers et al. 2007; Zhang et al. 2015; Zhu et al. 2014). MSC-EVs have also been demonstrated to have immunomodulatory capacities (Mokarizadeh et al. 2012) and anti-tumor activities, and their role in drug delivery has also been studied (Pascucci et al. 2014; Wu et al. 2013).

In animal models, MSC-EVs have been shown to specifically accumulate in the site of injury (Grange et al. 2014). This has also been seen with MSCs, although they are, at least first, trapped in the lungs when administered intravenously (Gao et al. 2001; Kerkela et al. 2013; Mahmood et al. 2003; Nystedt et al. 2013; Schrepfer et al. 2007). Amarnath et al. have shown that MSCs trapped in the lungs deliver their systemic immune suppression via MSC-EVs (Amarnath et al. 2015). There has also been a case study with MSC-EVs administrated to a human to treat GVHD and the results indicated

that MSC-EVs may have potential for the treatment of GVHD (Kordelas et al. 2014).

One of the mechanisms behind the beneficial effects of MSC-EVs has been suggested to be the delivery of mRNA and miRNA (Chen et al. 2010; Tomasoni et al. 2013). Other forms of biological information transmitted by EVs include proteins, glycoproteins, and lipids. MSC-EVs are hypothesized to have advantages over MSCs in clinical use in the future (Rani et al. 2015).

1.2.2 TISSUE SOURCES

MSCs have been derived from many different tissues. The most well characterized MSCs are BM-derived MSCs (BM-MSCs). Other, well characterized MSC sources include adipose tissue (AT)¹, cord blood (CB), umbilical cord (UC), and placenta (Mattar and Bieback 2015). The afterbirth (such as placenta and umbilical cord) is considered a good source of MSCs as these tissues are abundantly available and would otherwise be biological waste. Also, excess AT removed by liposuction is a medical waste and is thus available for other uses (Strioga et al. 2012). The collection of BM is an invasive procedure which always contains a risk of infection (Hass et al. 2011), making alternative sources to bone marrow very attractive.

All MSCs are not equal and MSCs from different tissues vary. The cells are in principal similar, but some variance is seen in their differential proliferation potential, surface marker expression, and functional capacities. Also, the gene expression profiles of MSCs from different tissues have been shown to have significant differences between different tissues (Wagner et al. 2005). Along with AT-MSCs, the initial CFU-F numbers are described as the highest, as compared to BM- and CB-derived MSCs (CB-MSCs) (Kern et al. 2006). Although the initial number of MSC in CB is very low, the proliferative capacity of CB-MSCs and other afterbirth tissue-derived MSCs is reported to be higher than that of MSCs from adult tissues (Barlow et al. 2008; Kern et al. 2006). An example of the variance in the immunophenotype of MSCs from different tissues is the CD34 positivity of AT-MSCs, reported at least at early stages *in vitro* (Maumus et al. 2011; Traktuev et al. 2008), whereas MSCs from other sources are negative for this marker (see Table 1). Variance in the differentiation capacities has been observed among MSCs from different sources. CB-MSCs are reported to differentiate poorly into adipocytes *in vitro* (Bieback et al. 2004; Chang et al. 2006b; Manca et al. 2008; Montesinos et al. 2009; Yoshioka et al. 2015; Zhang et al. 2011), while *in vivo* it has been shown that dental pulp derived MSCs differentiate into dentin and not into bone as do similarly handled BM-

¹ AT-derived MSCs (AT-MSCs) are named with a variety of names and the name adipose derived stem/stromal cells (ASC) is currently the most accepted term for these cells (Lindroos et al. 2011). These cells are however named AT-MSCs in this thesis to indicate their similarity with MSCs from other sources.

MSCs (Gronthos et al. 2000). The capacity of MSCs to support the construction of functional hematopoietic niche has recently been shown to be restricted to BM-derived MSCs, as opposed to AT-MSCs and umbilical cord-derived MSCs (UC-MSCs) (Reinisch 2015).

The comparison of immunomodulatory capacities of MSCs from different tissues has been reviewed by Mattar and Bieback (2015). Although it has been reported that MSCs from all tested sources are capable of suppressing immune reactions *in vitro* there is some variability in their capacities (Mattar and Bieback 2015). In many studies, AT-MSCs, for instance, have been demonstrated to have enhanced immunosuppressive capabilities compared to BM-MSCs, though conflicting results also exists. The heterogeneity in the experimental protocols makes it difficult to compare the immunosuppressive capabilities of MSCs from different sources (Mattar and Bieback 2015). The angiogenic supporting potential of MSCs has also been described to vary between different sources. AT-MSCs have been demonstrated to have significantly greater angiogenic potential than BM-MSCs (Kim et al. 2007). As these results are to some extent conflicting and most of the comparative studies have been conducted *in vitro*, the real difference in the capacities of MSCs from different sources still needs to be studied further to establish whether one source is more beneficial than another in therapy.

1.2.3 CLINICAL USE OF MSCs AND CLINICAL TRIALS

The basis for using MSCs for clinical purposes relies on their immune regulation capacity, hematopoiesis, and tissue regeneration supporting functions, as well as on their migratory capacity. Numerous promising *in vitro* studies with animal models have rapidly made MSCs a major focus of cell-based therapies (see Figure 1).

In the first trials, autologous MSCs were utilized in the treatment of patients suffering from hematological malignancies, without any indications of adverse effects (Lazarus et al. 1995). Osteogenesis imperfect was the first disease treated with allogenic MSCs in a clinical study (Horwitz et al. 2002). The effects of allogenic MSCs have also been studied in a clinical trial with patients with inborn metabolic errors (Koc et al. 2002). Although the clinical results of the first trials did not clearly demonstrate the efficacy of MSCs they were important as they provided preliminary evidence that MSCs can be administered without adverse effects, indicating the safety of MSC therapy (Singer and Caplan 2011).

Since then, the number of clinical trials has increased enormously, with the number of completed or ongoing clinical trials being nearly 350 in 2013 (Ankrum et al. 2014), and rising close to 500 in 2015 (Squillaro et al. 2016). The current number of clinical trials is 652 including completed, terminated, and ongoing studies (data from clinicaltrials.gov, March 2016, with search terms “Mesenchymal Stem cells”, “Mesenchymal Stromal Cells”, “Multipotent stromal cells”, and “bone marrow stromal cells”). Most of the

clinical trials occur, at an early phase, which demonstrates that the therapeutic effectiveness still needs to be proven. Based on the first systematic review and meta-analysis that comprehensively summarizes the safety of systemic MSC administration, this therapy appears to be safe (Lalu et al. 2012). The long term safety of MSC based cell therapies is still poorly investigated, which hinders the translation of these therapies into clinical practice (Squillaro et al. 2016).

GVHD is an adverse condition where the transplanted cells attacks host tissues and organs and it occurs in 30-80% of recipients after allogeneic hematopoietic stem cell transplantation (Squillaro et al. 2016). The capacity of MSCs to treat GVHD has been extensively studied since the first case study reported by Le Blanc et al. in 2004 (Le Blanc et al. 2004). Data from most studies suggest that MSCs are effective for GVHD (Ankrum et al. 2014; Sharma et al. 2014; Squillaro et al. 2016), although also conflicting data exists (Parekkadan and Milwid 2010; von Bonin et al. 2009). Besides GVHD, MSCs have been used to treat several other diseases and conditions including cardiovascular diseases, neurologic diseases, autoimmune diseases, organ transplantation, wound healing, and defects in bone and cartilage (Table 3).

Table 3. *Examples of reported clinical trials and pilot studies with MSCs*

target of therapy	MSC type	Reference
supporting function HSC transplantation	autologous BM-MSC, HLA- identical/haploidentical- related BM-MSC	(Macmillan et al. 2009; Meuleman et al. 2009)
GVHD	allogenic BM-MSCs, identical/haploidentical- related BM-MSC, allogenic AT-MSCs	(Arima et al. 2010; Fang et al. 2007; Kebriaei et al. 2009; Le Blanc et al. 2004; Le Blanc et al. 2008; Ringden et al. 2006; Zhao et al. 2015)
stroke	autologous BM-MSC	(Bang et al. 2005; Honmou et al. 2011; Lee et al. 2010)
myocardial infarction	allogenic/autologous BM-MSC	(Chen et al. 2004; Hare et al. 2009; Mohyeddin-Bonab et al. 2007; Yang et al. 2010)
kidney transplantation	allogenic AT-MSCs, autologous BM-MSC	(Perico et al. 2011; Vanikar et al. 2011)
chronic obstructive pulmonary disease (COPD),	allogenic BM-MSCs	(Weiss et al. 2013)
osteogenesis imperfecta	allogenic BM-MSCs	(Horwitz et al. 2002)
cartilage lesions	autologous BM-MSC	(Wakitani et al. 2011)
wound healing	autologous BM-MSC	(Falanga et al. 2007)
liver diseases	autologous BM-MSC, allogenic UC-MSC	(Kharaziha et al. 2009; Mohamadnejad et al. 2007; Zhang et al. 2012)
Crohn's disease	allogenic BM-MSCs autologous AT-MSCs, autologous BM-MSC	(de la Portilla et al. 2013; Duijvestein et al. 2010; Garcia-Olmo et al. 2005; Liang et al. 2012)
inborn metabolic disorders	allogenic BM-MSCs	(Koc et al. 2002)
systemic lupus erythematosus (SLE)	allogenic UC-MSC, allogenic BM-MSC	(Liang et al. 2010; Sun et al. 2010)
multiple sclerosis	autologous BM-MSC	(Karussis et al. 2010; Llifri et al. 2014)
Parkinson's disease	autologous BM-MSC	(Venkataramana et al. 2010)
amyotrophic lateral sclerosis (ALS)	autologous BM-MSC	(Karussis et al. 2010; Kim et al. 2014; Mazzini et al. 2003)
spinal cord injury	autologous AT-MSCs	(Ra et al. 2011)
cerebral palsy (CP)	autologous BM-MSC	(Wang et al. 2013)

It has also been suggested that because of their capacity to migrate to tumour environment, MSCs may be useful as cellular vehicles for targeted delivery of chemotherapeutics into tumours (Adjei and Blanka 2015). Virus

transduced MSCs have already been used in clinical studies to deliver tumour destroying virus into tumours such as neuroblastoma (Garcia-Castro et al. 2010). Although MSCs themselves are not shown to be tumorigenic, (Tarte et al. 2010) their tumour migrating capacity and immunosuppressive effects may also be a threat in a case that the recipient has an un-known tumour when treated with MSCs. In animals with a pre-existing tumour, MSCs have been shown to promote tumour growth (Djouad et al. 2006). Thus, there are still several issues to resolve before all the potential held by MSCs and their possible adverse effects in clinical settings are known.

1.3 CULTURE OF MSCs

There are several methods for culturing MSCs. The beginning of the culture usually starts with the isolation of mononuclear cells (MCs) when using tissues such as BM, CB, or peripheral blood as starting material. These sources do not need to be mechanically or enzymatically treated, as do such sources as adipose tissue, placenta, and umbilical cord (Dehkordi et al. 2015; Gimble and Guilak 2003; Parolini et al. 2008). MSC cultures have also been established by enriching first certain cell populations using magnetic selection (Tondreau et al. 2005; Zhang and Chan 2010). Although these selections may enrich MSCs, the resulting cell populations are still heterogeneous and the majority of the isolated cells do not give rise to CFU-F (Ho et al. 2008).

Cell isolation is followed with plating of the cells. Cells are most often plated on uncoated culture flasks made of plastic or on flasks coated with a protein, usually extracellular matrix protein (Ho et al. 2008). MSCs are assumed to adhere within a few days after initial plating, and the following media changes remove the contaminating non-adherent hematopoietic cells (Bara et al. 2014). It has been suggested that the variation between groups in these initial culture procedures may result in differences in the outcome of MSC cultures and the following cell-based therapies conducted with these cells (Bara et al. 2014).

Also seeding density and confluency of cultures have been shown to impact the properties of MSCs. MSCs seeded at low density have been shown to have the highest capacity to proliferate (Both et al. 2007; Colter et al. 2000). It has also been demonstrated that if MSC cultures are grown to confluence, the proliferative capacity of the cells is diminished (Lennon et al. 2012). In contrast, the effect of culturing MSCs to their confluence does not affect their capacity to differentiate (Lennon et al. 2012). Ylöstalo et al. have shown that MSCs in the middle of a dense cell colony are partially differentiated, compared to cells in the outer part of the colony. This difference can be reversed when the cells are re-plated. When re-plated at clonal densities, the cells from the outer and inner part of the initial colony become indistinguishable (Ylostalo et al. 2008). Thus the sub-culturing of

MSCs on a regular basis seems to be important when propagating these cells (Lennon et al. 2012).

Culture conditions have been shown to impact the properties of MSCs. Many of the cell preparations given different names may just be creations of the conditions they have been cultured in. Roobrouck et al. demonstrated that MSCs and MAPCs have different properties that are at least partially mediated by culture conditions (Roobrouck et al. 2011a). Roobrouck et al. specifically showed that changing the MSC culture condition to MAPC culture condition shifted the MSC gene expression profile toward the MAPC gene expression profile and vice versa (Roobrouck et al. 2011a). Others have also demonstrated that different culture conditions change the gene expression profile of MSCs (Wagner et al. 2005) and it has been noted that slight experimental modifications can lead to the production of completely different cell population (Ho et al. 2008).

1.3.1 CULTURE MEDIA

MSCs have been cultured in a variety of different culture media. The basic media is most commonly DMEM/DMEM F12 or alpha MEM (Bara et al. 2014), supplemented with various supplements. The glucose concentration used in MSC culture media is 1,000 mg/ml (5.5 mM) which approximates normal blood sugar levels *in vivo*. This glucose concentration has been demonstrated to have better capacity to support MSC growth compared to the higher glucose concentration of 4,500 mg/ml (Sotiropoulou et al. 2006). Glutamine is an essential nutrient needed in cell culture. It is unstable, leading to formation of ammonia in cell cultures and finally to cell growth inhibition. The use of Glutamax™ (dipeptide L-alanine-L-glutamine) provides L-glutamine in a more stable form and it has proved to have better capacity to support the growth of MSCs (Sotiropoulou et al. 2006) than the use of L-glutamine. For successful cell culture, a mixture of factors for cell attachment, growth, and proliferation is also needed. FBS is the most common supplement containing these essential factors in MSC cultures. MSCs cultured from different sources seem to have different needs regarding the medium. In their studies, Wagner et al. noticed that MSCs from CB could not be obtained using the same low serum conditions with few additives as for BM-MSCs (Wagner et al. 2005). CB-MSCs seem to need more FBS or other supporting components in the medium (Kogler et al. 2004). Different supplements have been used to enhance the growth of MSCs; some of these are listed in table 4.

Table 4. Growth supporting factors used in MSC culture media

growth factor	cell type	reference
bFGF	CB-MSC, BM-MSC	(Gharibi and Hughes 2012; Jung et al. 2010; Lee et al. 2004b; Ng et al. 2008; Zhang et al. 2011)
platelet derived growth factor-BB (PDGF-BB)	BM-MSC	(Gharibi and Hughes 2012; Ng et al. 2008)
epidermal growth factor (EGF)	BM-MSC	(Gharibi and Hughes 2012)
dexamethasone (DX)	CB-MSC, BM-MSC	(Xiao et al. 2010; Zhang et al. 2011)
TGF- β	BM-MSC	(Jung et al. 2010; Ng et al. 2008)
stem cell factor (SCF)	CB-MSC	(Zhang et al. 2011)
ascorbic acid	BM-MSC	(Gharibi and Hughes 2012; Jung et al. 2010)
Wnt3	BM-MSC	(Gharibi and Hughes 2012)
IL-3	CB-MSC	(Zhang et al. 2011)

1.3.1.1 FBS and its substitutes

FBS has been the most commonly used supplement in MSC culture media. The concentration of FBS varies from 2% up to 30% (Kogler et al. 2004; Pittenger et al. 1999; Reyes et al. 2002), 10% being the most common concentration. Although FBS supports the MSC growth well, there are several disadvantages associated with it, one being the huge lot-to-lot variation (Tekkatte et al. 2011). The major disadvantages pertain to the safety of using FBS for culturing cells for clinical purposes. Animal-derived components hold the risk of possible contamination with viruses, bacteria, mycoplasma, yeast, fungi, and endotoxins (Tekkatte et al. 2011). It has also been demonstrated that FBS cultured MSCs may induce antibody production against FBS when administered to patients (Horwitz et al. 2002; Sundin et al. 2007).

For clinical purposes the use of xeno-free culture conditions are encouraged by regulators. The term xeno-free means a product that does not contain any animal-derived components. Several different substitutes for FBS have been tested (listed in Table 5). These medium supplements include human serum, plasma, CB serum, and platelet derivatives (Tekkatte et al.

2011). Although chemically defined medium would be the optimal solution, the design of the composition of the medium is extremely challenging since the effect of individual growth factors on MSC growth is poorly understood (Tekkotte et al. 2011). Platelet lysate (PL), which is derived from platelet rich plasma (PRP), has been the most studied FBS substitute and it is an acceptable medium supplement according to regulators (Wuchter et al. 2015). The use of PL instead of FBS does not necessarily make the culture medium xeno-free as porcine-derived heparin is usually needed to prevent the clotting of coagulation factors-containing PL. The use of heparin has been accepted as it is an approved pharmaceutical. Heparin-free medium using serum converted PL instead PL containing coagulation factors has also been demonstrated to support MSC growth (Mojica-Henshaw et al. 2013). In addition, a commercially available PL-product with reduced coagulation factors as a supplement in culture medium without heparin has already been tested in MSC cultures. The capacity of the coagulation factor reduced PL to support MSC growth might, however, be diminished (Juhl et al. 2016).

Table 5. Pros and cons of FBS substitutes tested in MSC cultures.

FBS substitute	+	-	reference
autologous serum	high proliferation rate	diminished differentiation, limited availability	(Shahdadfar et al. 2005)
allogenic serum	expansion kinetics comparable with FBS at early passages	inhibitory effects on growth and survival of MSCs and decelerated proliferation from p4 on	(Bieback et al. 2009; Shahdadfar et al. 2005)
thrombin activated platelet lysate	expansion kinetics comparable with FBS at early passages	decelerated proliferation from p4 on, requires fresh preparation, complicate preparation	(Bieback et al. 2009)
PL (plasma-containing)	high expansion rate, no lot-to-lot variability	need of porcine derived heparin	(Bieback et al. 2009)
serum converted PL	heparin-free culture, proliferative capacity comparable to plasma-containing PL	complicate preparation	(Mojica-Henshaw et al. 2013)
coagulation factor reduced PL (Stemulate™)	heparin-free culture	diminished proliferation compared to PL	(Juhl et al. 2016)
CB/placental serum	High expansion capacity, availability	no attachment to plates after p3	(Julavijitphong et al. 2014; Shafaei et al. 2011; Shetty et al. 2007)

1.3.2 OXYGEN CONCENTRATION

In vitro culture of cells is usually performed in incubators in normal atmospheric oxygen (O₂) concentration in the presence of 5% carbon dioxide (CO₂). 5% CO₂ is optimal for the maintenance of appropriate pH conditions and it resembles the CO₂ concentration *in vivo* (Csete 2005; D'Ippolito et al. 2006). The O₂ concentration is not usually controlled due to the more complicated controlling procedures as, besides the surrounding atmospheric O₂ conditions, the O₂ tension depends on the depth of medium, density of cells, and cellular respiration (Csete 2005). Thus the standard O₂

concentration in incubators supplied by room air is 20% (Haque et al. 2013). The physiological O₂ level is significantly lower. The O₂ concentration varies from tissue to tissue, being 1% in cartilage and bone, 1-6% in BM and 4-14% in circulation, and 3-8% in placenta (Haque et al. 2013; Sullivan et al. 2006).

It has been reported that the proliferation of stem cells is enhanced and their apoptosis is reduced in low O₂ concentrations (Csete 2005). Also, the proliferation of MSCs has been demonstrated to be enhanced when cultured in low O₂ concentrations (Carrancio et al. 2008; Dos Santos et al. 2010; Estrada et al. 2012; Tsai et al. 2011). Although low O₂ concentrations enhance the proliferation of MSCs, this effect is only seen clearly at late passages (Fehrer et al. 2007; Tsai et al. 2011). Besides the supportive effect on the proliferation of MSCs, low O₂ concentrations are also known to reduce the genetic instability and oxidative stress in MSCs (Estrada et al. 2012).

A few reports propose that different cell populations are generated under low O₂ concentrations. MIAMI cells have been cultured from BM in low O₂ concentrations on fibronectin (FN)-coated culture plates in the medium supplemented with 5% FBS. These cells have been reported to have extensive proliferative capacity and a wide *in vitro* differentiation repertoire (D'Ippolito et al. 2004). The same group also cultured MIAMI cells in different O₂ concentrations (1%, 3%, 5%, 10%, and 21%) and noticed that the cells cultured in 3% O₂ concentration have the highest capacity to proliferate (D'Ippolito et al. 2006).

Buchheiser *et al.* reported that cells with different properties can be derived from CB in different O₂ concentrations (5% and 20%) (Buchheiser et al. 2012). In 20% O₂, they were able to generate both CB-MSCs and so called USSCs. USSCs are defined as differing from CB-MSCs by their *Homeobox (HOX)* gene expression pattern, *Delta-like 1 homolog (DLK-1)* expression, and by their adipogenic differentiation capacity (Kluth et al. 2010). *HOX* genes are known to be involved in tissue specification and cell identity during embryonic development and the *HOX* expression pattern of murine MSCs points to the topographic origin of the cells (Ackema and Charite 2008). The cells generated in 5% O₂ concentrations differed from both CB-MSCs and USSCs (Buchheiser et al. 2012). They also showed that growth kinetics of the cells generated in 20% O₂ concentration did not change when converted to 5% O₂ concentration. On the other hand, the cells generated in 5% O₂ concentration showed decreased proliferation capacity and they seemed to be less adaptive to higher O₂ concentrations. Buchheiser et al. hypothesized that culture conditions during the generation of cells is more critical than temporary changes in O₂ concentrations. Thus different cell populations may be generated at different frequencies depending on the O₂ concentration (Buchheiser et al. 2012).

An example of the influence of environmental conditions on the functionality of MSCs is the effect of hypoxia on these cells. With hypoxic (1%) O₂ concentration, MSCs have been shown to increase the production of trophic factors to enhance angiogenesis and immune modulatory activity

(Madrigal et al. 2014). These examples indicate the responsiveness of MSCs to the surrounding environment.

1.3.3 CULTURE OF MSCs FOR CLINICAL USE

MSCs have been cultured from different sources in a variety of different conditions. Clinical trials are also conducted with MSCs produced with different culture protocols and consequently the data obtained from these trials may be difficult to interpret. A position paper written by researchers, clinicians, and regulators (Wuchter et al. 2015) gives recommendations and relevant information that promote the goal of having a common standard for the production of MSCs for clinical use. The paper presents recommendations that pertain to the source of MSCs, media composition, and duration of cell expansion, as well as recommendations for storage and measures of quality controls. As BM is the most commonly used source of MSCs, the position paper concentrates on this tissue. Xenogeneic-free medium with defined and certified ingredients is recommended, with PL recommended as the supplement for the medium. The duration of culture should be as limited as possible, counted by means of the population doubling (PD) numbers (Wuchter et al. 2015).

For quality control testing, it is recommended that the MSCs should be positive for CD73, CD90, and CD105 and negative for CD45. Measuring other markers is recommended depending on the source of the cells and their therapeutic use (see Table 1). No recommendations can be given about measuring the immunomodulatory capacity of MSCs as the existing *in vitro* assays do not necessarily reflect their *in vivo* capacity. Although there is no indication of adult MSCs having tumorigenic potential, the occurrence of chromosomal abnormalities should be checked by karyotyping. The monitoring of PD time is recommended to help to detect highly proliferating, possibly transformed cell populations (Wuchter et al. 2015).

1.3.3.1 Regulation and good manufacturing practice (GMP)

Culture expanded MSCs are classified as advanced therapy medicinal products (ATMPs) according to EU legislation (Regulation (EC) 1394/2007 on advanced therapy medicinal products). Subclasses of ATMPs include gene therapy medicinal products (GTMPs), somatic cell therapy medicinal products (sCTMPs), and tissue engineered medicinal products (TEPs) (Celis et al. 2015). CTMPs and TEPs, also referred to as cell-based medicinal products (CBMPs), differ from cell and tissue transplants as they have undergone additional manipulation and they can be used for a function in the recipient that differs from the original function in the donor (Celis et al. 2015). MSCs belong to the group of sCTMPs.

As ATMPs are complex pharmaceuticals, a risk-based approach has been developed to enhance the regulatory flexibility needed for the regulation of these products (Celis et al. 2015). The Committee for Advanced Therapies (CAT) within the European Medicines Agency (EMA) is responsible for all regulatory procedures concerning ATMPs in the EU (Ancans 2012). It offers classification, certification, and evaluation procedures concerning ATMPs, and thus also all regulatory procedures for MSCs. CAT reviews the quality, safety, and efficacy of ATMPs prior to marketing authorization. After authorization, ATMPs are subject to a strict post-authorization surveillance program to ensure the patient safety (Celis et al. 2015). Alternatively, an ATMP therapy product may be considered for a national authorized procedure under the hospital exemption. For hospital exemption authorization, the product has to be prepared on a non-routine basis according to specific quality standards, and it has to be used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner (Ancans 2012). The national authorities (in Finland Finnish Medicines Agency) have a crucial role in the supervision of clinical trials of ATMPs as well as the supervision of hospital exemptions.

Prior to clinical studies, non-clinical studies are mandatory for the assessment of risks related to a new ATMP. Non-clinical studies should be performed in relevant animal models to demonstrate the proof of principle for the product and to define the pharmacological and toxicological effects. Also, the safe doses for subsequent clinical studies and the route of administration should be studied (Celis et al. 2015; Salmikangas et al. 2010). The beneficial effects of MSCs have been demonstrated in a wide range of pre-clinical development disease models and the results of clinical studies have led to the conclusion that MSC applications are safe and feasible (Ancans 2012).

One of the central elements in the ATMP regulation is the GMP requirements that are mandatory to ensure safety and reproducibility of the product. For the culture of MSCs for clinical studies, a formal approval from competent regulators is needed. This approval is only granted if the cells are cultured according to GMP. Thus, the cells need to be cultured under the highest standards of sterility, quality control, and documentation, in accordance with a standard operating procedure. The basic GMP requirements mean that all manufacturing processes are clearly defined and systematically reviewed. The critical steps (including processes, equipment, and facilities) of the manufacture need to be validated, the personnel must be appropriately qualified and trained, traceability of all materials must be arranged and instructions must be clearly written, with records of all the steps during manufacture being mandatory (on-time recording). Also all significant deviations need to be fully recorded and investigated, and preventative actions must be implemented. To assure the quality of the cell product, quality controls (process and final product) must include bacteriological, phenotypic, viability, safety, and efficacy tests. The release

criteria are product dependent and must be defined separately for each therapeutic product.

2 AIMS OF THE STUDY

The aims of this study were:

1. To establish an efficient culture method to obtain MSCs from CB.
2. To establish a robust culture method to culture BM-MSCs for clinical use.
3. To gain knowledge about the impact of different culture conditions on MSC characteristics and functionality.
4. To gain basic knowledge about the immunomodulatory mechanisms of MSCs.

3 MATERIALS AND METHODS

3.1 ETHICS

The study was approved by the ethical review board of the Finnish Red Cross Blood Service and the Ethical Committee of the Hospital District of Helsinki and Uusimaa. Human CB and BM were collected from voluntary healthy donors after written informed consent. Only CB-units unsuitable for clinical banking due to a too low blood volume or cell amount were used in the studies.

3.2 METHODS

Materials and methods used in the studies are described in detail in the original publications (I-IV) and are listed in Table 6.

Table 6. *Materials and Methods used in publications I-IV in the thesis.*

Method	used in study
Cell and EV isolation methods	
- density-gradient centrifugation	
• isolation of MCs from CB	I, II
• isolation of MCs from BM	III
• peripheral blood MC (PBMC) isolation	II, III, IV
- magnetic bead cell separation	
• isolation of CD3 ⁺ T cells	IV
- ultracentrifugation	
• EV collection from cell culture supernatant	IV
Preparation of platelet-derived cell culture supplements	III
Cell culture	
- culture of CB-MSCs	I, II, IV
- culture of BM-MSCs	III, IV
- MSC differentiation assays	II, III
• bone, adipose and cartilage	
Cell functionality tests	
- T cell suppression assay	
• co-culture of PBMCs and MSCs	II, III
• co-culture of T cells and MSCs	IV
- angiogenesis assay	II
• tube formation assay of endothelial cells	
Fluorescence based characterization of cells	
- Flow cytometry	
• immunophenotype of MSCs	II, III, IV
• immunophenotype of T cells	IV
- Immunofluorescence microscopy	IV
• expression of CD73 and CD39 in MSCs	
Karyotyping	III
<i>HOX</i> expression	II
- Reverse transcription polymerase chain reaction (RT-PCR)	
VEGF expression	II
- Quantitative real-time polymerase chain reaction (qRT-PCR)	
- Enzyme-linked immunosorbent assay (ELISA)	
EV analysis	IV
- Nanoparticle tracking analysis (NTA)	
Nucleotide measurements	IV
- High-performance liquid chromatography (HPLC)	

3.2.1 DIFFERENT CULTURE MEDIA

Different culture media used in the CB-MSc studies are listed in table 7 and in table 8 for the BM-MSc studies.

Table 7. *The compositions of culture media used in the CB-MSc studies. StdM was used as standard growth medium of CB-MSc (publications I, II, IV) and in the functional studies of CB-MSc (publication II). M1 medium was used in the long term culture studies of CB-MSc and in the functional studies of CB-MSc (publication II). M2 medium was used in the functional studies of CB-MSc (publication II). M3 medium was used as an assay medium in the functional studies of CB-MSc (publication II).*

medium component	StdM	M1	M2	M3
alpha-MEM Glutamax™	x	x	x	x
penicillin	100U/ml	100U/ml	100U/ml	100U/ml
streptomycin	100µg/ml	100µg/ml	100µg/ml	100µg/ml
FBS	10%	5 %	5 %	5 %
DX	50 nM	-	-	50 nM
EGF	10 ng/ml	-	10 ng/ml	10 ng/ml
PDGF-BB	10 ng/ml	10 ng/ml	10 ng/ml	-

StdM = Standard growth medium, M1= Medium 1 and M2 = Medium 2, M3 = Medium 3,
X=included in medium

Table 8. *The composition of growth media used for the BM-MSc studies (publication III).*

medium component	FBS-medium	PL1-medium	PL2-medium
DMEM-LG	x	x	x
penicillin	100U/ml	100U/ml	100U/ml
streptomycin	100µg/ml	100µg/ml	100µg/ml
FBS	10%	-	-
Heparin	-	40 IU/ml	40 IU/ml
PL1*	-	10%	-
PL2*	-	-	0.5%
AB-plasma	-	-	2.5%

FBS = fetal bovine serum, PL1 = platelet lysate 1 supplement, PL2 = platelet lysate 2 supplement

*Different platelet concentration in lysate

X=included in medium

4 RESULTS

4.1 AN EFFICIENT METHOD TO CULTURE MSCs FROM CB

4.1.1 THE SUCCESS RATE OF OBTAINING MSCs FROM CB

CB has proven to be a challenging material to obtain MSCs from. In our laboratory, in the early stages of the development of the method to culture MSCs from CB, several trials were made using either low serum (2% FBS) containing medium with several growth factors or high serum (15% FBS) containing medium with fewer growth factors (Laitinen and Laine 2007). These methods were carried out in normal atmospheric O₂ concentration. As the success rate of obtaining MSCs with these methods was low (data not shown), the method was further improved. The standard growth medium (StdM, Table 7) was developed based on information on MSC supporting factors in literature.

With the improved method, MSCs were successfully generated from 14 out of 16 CB-units, which corresponds to a success rate of 87.5%, when cells from CB were cultured in StdM on FN-coated plates in 3 % O₂ concentration. The mean volume of the CB units was 58.6 ± 19.2 ml. MSC could even be obtained from small CB-units of 42 ml in volume. The mean MC count after density gradient centrifugation was 382.6 ± 124.2. There was no correlation between the CB unit volume or MC number and MSC amount in passage 1 (p1) (R² = 0.0374 and R² = 0.0023, respectively). The storage time of CB-units before processing was over 19 h (mean 23.97 ± 5.88 h, publication II Table 2). The success rate of obtaining MSCs from almost 90% of CB-units that were stored for over 19 hours (and included even small units) is much higher than the success rate reported earlier in literature for human CB-MSCs.

4.1.2 THE IMPACT OF CULTURE CONDITIONS ON THE PROLIFERATION OF CB-MSCs

Several growth factors are thought to be beneficial for MSC growth. In our laboratory, the importance of different components in the StdM on cell proliferation was tested by excluding growth factors from medium. These tests indicated PDGF-BB to be a critical factor for efficient CB-MSC proliferation since the proliferation was radically diminished without PDGF-BB (data not shown) and therefore it was included in all growth media used for CB-MSCs in the studies of this thesis. Also O₂ concentration in cell culture has been demonstrated to influence cell proliferation.

In this thesis, the impact of culture conditions on the proliferation of CB-MSCs was studied. To see the effects of different culture media on long term proliferation of CB-MSCs, the cells were cultured in parallel in two different media, StdM and M1 (Table 7), from passage 2 on. For the purpose of investigating the impact of O₂ on the long term cultures of CB-MSCs, the cells were also cultured in two different O₂ concentrations (3% and 20%).

The results showed that CB-MSCs from the studied cell batches were capable of proliferating for up to 17 passages before senescence. Although the capacity of CB-MSCs to proliferate differed between CB-MSC batches, MSCs cultured in StdM, which contained more growth factors compared to M1 medium, proliferated better and reached higher PD numbers in shorter time than CB-MSCs cultured in M1 medium, irrespective of the O₂ concentration. The combination of an optimal culture medium and 3 % O₂ concentration gave the best results in terms of the CB-MSC growth. CB-MSCs showed the greatest capacity to proliferate when cultured in StdM in 3% O₂ concentration. The supportive effect of 3% O₂ concentration on cell proliferation was seen more clearly at late passages than at early passages (Table 9, Figure 3 and publication II Figure 3).

Table 9. *The proliferative capacity of the MSCs in different culture conditions in the long term cultures of CB-MSCs. The numbers of cumulative PDs, the culture length in days (d) and passage numbers (p) reached by CB-MSCs from two different CB-units. (Modified from Laitinen et al 2016, publication II Figure 3).*

CB-unit name	391P						454T(7)					
	StdM			M1			StdM			M1		
medium	PD	d	p	PD	d	p	PD	d	p	PD	d	p
3% O ₂	51	57	16	42	85	17	48	59	17	32	71	14
20% O ₂	47	63	17	35	66	14	40	56	15	26	66	13

StdM = Standard growth medium, M1= Medium 1




Figure 3 Long term culture of CB-MSCs in two different media and in two different oxygen concentrations. Cells from CB-units (A) 391P and (B) 454T(7) cultured from passage 2 until senescence. The supportive effect of 3 % O₂ on cell proliferation was more obvious at late passages. (Modified from Laitinen et al 2016, publication II Figure 3).

4.2 DEVELOPMENT OF CULTURE METHOD FOR CLINICAL-GRADE BM-MSCs

4.2.1 DEVELOPMENT OF PL SUPPLEMENTS

Efficient xeno-free expansion methods to culture MSCs for clinical use are strongly encouraged by regulators. Human platelet-derived supplements have been widely studied to find substitutes for bovine derived FBS. In this

thesis, two different platelet-derived PLs, PL1 and PL2, were produced for use as supplements in BM-MSc culture media (Table 8). PL1 was produced by pooling several PRP units that had been frozen once before pooling. PL2 was produced from platelet concentrates by efficiently lysing the platelets with five freeze-thaw cycles before pooling several of these units. The efficiency of these supplement-pools to support MSC growth were tested in a 5-7 day BM-MSc proliferation assay.

PL1 pools of different sizes (produced from different number of PRP units) were tested using 2–4 individual MSC batches as responder cells. The tested pools supported consistently the proliferation of BM-MSCs, with the cells reaching 3-6.2 PDs during the proliferation assay (publication III Table 2). The pools produced from two PRP units were noted to be as efficient in supporting MSC proliferation as those produced from 13 units. For PL2, all units used for the pool were individually tested and shown to support MSC growth at least as well as FBS-containing medium.

4.2.2 THE IMPACT OF CULTURE CONDITIONS ON BM-MSc PROLIFERATION

Efficient GMP-compliant methods are necessary for the expansion of a sufficient number of BM-MSCs for clinical needs from a limited amount of BM. In this thesis, two different GMP-compliant culture media, PL1 and PL2, were compared against FBS-medium (Table 8) in regard to their ability to support the proliferation of BM-MSCs at early passages of the cells (up to passage 2). We also tested the capacity of these different media to support the long term proliferation of BM-MSCs. The impact of O₂ concentration on the cell proliferation at early passages was also studied.

The short term cultures (up to passage 2) indicated that the PL1-medium had better capacity to support the growth of BM-MSCs regardless of O₂ concentration compared to PL2-medium as the PD time was significantly shorter when BM-MSCs were cultured in PL1-medium ($p=0.015$). There was no statistical difference observed in the PD times between FBS- and PL1-medium cultured cells. Also, there was no statistical difference in total cell yield or cumulative PDs between different culture conditions ($p = 0.42$ and 0.99 , respectively) (Figure 4). Though the difference was not statistically significant, there was a trend indicating that 3% O₂ concentration might support a shorter PD time (Figure 4c). The most obvious difference in PD times was observed between cultures of PL1-medium in 3% O₂ and PL2-medium in 20% O₂ ($p=0.04$), with the PD time at passage 2 being 1.7 ± 0.3 and 4.2 ± 2.0 days, respectively. The long term culture of BM-MSCs in different media also indicated the effectiveness of PL1-medium as PL1-medium cultured cells reached higher PD numbers (46) before senescence than PL2- and FBS-media cultured cells (27 and 38 PDs, respectively, publication III Figure 4).




Figure 4 Results from BM-MSC cultures in three different media and in two different oxygen concentrations. **(a)** Extrapolated cell yields from 20 ml of BM up to passage two. **(b)** Cumulative PDs and **(c)** PD time at different passages from BM-MC up to passage 2. Data represented as mean \pm SD. (From Laitinen et al. 2015, publication III Figure1)

As the PL1-medium proved to be the most potent proliferation medium of the media tested, it was chosen for further studies. The further studies were conducted in 20% O₂ concentration as the 3% O₂ concentration did not significantly enhance cell proliferation. The effectiveness in obtaining clinically relevant numbers of BM-MSCs in PL1-medium within two cell passages was studied in detail. The aim was to reach clinically relevant cell numbers (10⁹) starting from 20 ml of BM within two cell passages. This aim was reached with 73 % of the cultured BM batches within 21-35 days (publication III Figure 2). The main reason for not reaching this limit set for cell numbers was the initial quality of the BM sample (clots in BM sample). Thus with good quality BM samples, the success percentage was even higher.

4.3 CHARACTERISTICS OF MSCs AND THE IMPACT OF CULTURE CONDITIONS

4.3.1 PHENOTYPE

MSCs from both BM and CB expressed the typical MSC markers, as shown by immunophenotyping with flow cytometry. The cells were positive for CD13, CD29, CD44, CD49e, CD73, CD90, CD105, and HLA-ABC, and they were negative for CD14, CD19, CD34, and CD45. Differences in expression of HLA-DR and CD90 were seen when culturing the cells in different conditions.

BM-MSCs cultured in PL1-medium were constantly positive for HLA-DR but the level of positivity varied between cell batches, with 7.5%-66.1% of the cells expressing this molecule on their surface. The expression of HLA-DR was also seen on PL2-medium cultured cells. On FBS-medium cultured cells, no HLA-DR positivity was detected (publication III Figure 6).

With CB-MSCs, the flow cytometric analysis of the cells revealed the cell surface expression of CD90 to be lower on cells cultured in growth factor rich and DX-containing medium, StdM, compared to cells cultured in medium with less growth factors, M1. The expression of CD90 was sustained through the passages on the cell surface of the CB-MSCs cultured in M1 but it was clearly diminished on StdM cultured cells (publication II, Figure 4).

4.3.2 HOX FINGERPRINT

The *HOX* code has been introduced as a marker to distinguish CB-derived cell types, such as *HOX*-positive CB-MSC and *HOX*-negative USSC (Liedtke et al. 2010). In this thesis, to characterize the *HOX* fingerprint of CB-MSCs the expression of 39 *HOX* genes distributed among four clusters (ABCD) were tested by RT-PCR. The expression profile of 39 *HOX* genes showed varied distribution within the A-D *HOX* clusters in MSCs from different CB-units, indicating heterogeneity in CB-MSC populations of different cell batches. There were two batches of CB-MSCs expressing the genes from all

four clusters, two CB-MSc batches expressing the genes from ACD clusters, and one cell batch expressing the genes from BCD clusters. In two CB-MSc batches, there was almost no expression of the *HOX* genes in any of the clusters (publication II, Figure 2A). The *HOX* fingerprint indicated that there is heterogeneity in MSc populations obtained from CB.

Changes seen in the expression profile during passaging were minimal as only some minor differences of the expression profile within the same *HOX* gene group were detected (publication II, Figure 2B).

4.3.3 DIFFERENTIATION POTENTIAL

According to the minimal criteria set for MScs, these cells should have tri-lineage differentiation capacity, with the ability to differentiate into osteoblasts, adipocytes, and chondrocytes (Dominici et al. 2006). In this thesis, the differentiation capacity of CB- and BM-MScs was tested. While BM-MScs were found to have all these differentiation capacities, the differentiation capacity of CB-MScs was heterogenic as not all batches showed true tri-lineage differentiation.

Only two of the tested CB-MSc batches retained the tri-lineage differentiation capacity with the others showing the capacity to differentiate into only two of the three lineages (publication II Table3 and publication II Figure 1). 10 of the tested 12 CB-MSc batches were capable of differentiating into osteoblasts and 5 of 10 tested batches differentiated into chondrocytes. Adipogenic differentiation was tested with two different methods, the traditional and the enhanced method (with PPAR γ ligand), with positive differentiation seen in 1 of 9 CB-MSc batches when tested with traditional method and in 11 of 13 when using the enhanced method. Chondrogenic differentiation was detected with 5 of the 10 tested CB-MSc batches (publication II Table3 and publication II Figure 1).

BM-MScs were showed to have the capacity to differentiate into all three lineages (publication III Figure 5). Osteogenic differentiation was conducted using two different osteogenic differentiation media: FBS-containing and PL1-containing differentiation media. When the differentiation was conducted in FBS-containing osteogenic differentiation medium, BM-MScs cultured in PL1-supplemented growth medium did not show strong osteogenic differentiation potential as the accumulation of calcium deposits was modest. In contrast, conducting the differentiation of BM-MScs in PL1-supplemented differentiation medium resulted in notably stronger differentiation (publication III Figure 5c and 5d).

4.4 THE IMPACT OF CULTURE CONDITIONS ON MSC FUNCTIONALITY

4.4.1 THE CAPACITY OF MSCs TO SUPPORT ANGIOGENESIS

To study the angiogenic supporting capacity of CB-MSCs cultured in different media, their ability to produce angiogenic factor, VEGF, was investigated with qRT-PCR and ELISA tests and their capacity to support tube formation of endothelial cells was verified in an *in vitro* angiogenesis assay.

CB-MSCs expressed VEGF on mRNA and on protein levels. The VEGF mRNA expression was up-regulated in cells primed for five days in M1 and M2 media, the media without DX (fold change difference values 3.7 and 4.3, respectively), as compared to StdM primed cells. A similar difference was detected on the protein level with CB-MSCs first primed in different media (StdM and M1) and then transferred into identical culture medium (M3) for 21h. The capacity of the CB-MSCs to produce VEGF varied between tested CB-MSc batches but the production was higher with cells primed in M1 medium (publication II Figure 5A and B).

In the *in vitro* angiogenesis assay, the CM of CB-MSCs was able to support tubule formation of endothelial cells. To compare this capacity in CB-MSCs primed in different media, the cells were first cultured in either StdM or M1 media and then transferred into the same medium (M3) for 21h before the collection of CM. The CM produced by M1 primed cells showed significantly better capacity ($p < 0.001$) to support tube formation than the CM of StdM primed cells (publication II, Figure 5C).

4.4.2 THE CAPACITY OF MSCs TO SUPPRESS T CELL PROLIFERATION

The capacity of both BM- and CB-MSCs to suppress T cell proliferation was tested with an *in vitro* co-culture assay of MSCs and peripheral blood MCs (PBMCs) in which T cells were activated with anti-CD3 antibody. Both BM- and CB-MSCs had the capacity to suppress T cell proliferation.

The capacity of CB-MSCs to suppress T cell proliferation differed significantly depending on whether the cells were primed in media with or without DX supplementation (StdM vs. M1 and M2). The suppression capacity was significantly diminished if cells were primed in M1 and M2 media, compared to StdM primed cells ($p < 0.01$ and $p < 0.05$, respectively, publication II Figure 6).

With BM-MSCs, there was no statistically significant difference detected in the MSCs' capacity to suppress T cell proliferation when they were cultured in different culture conditions (different media PL1, PL2 and FBS and different O₂ concentrations, 3% and 20%, $p = 0.14$) (publication III Figure 7).

Table 10. Summary of the results from characterization and functionality studies of CB- and BM-MSCs cultured in different media.

character/ functionality	general criteria*	BM-MSCs			CB-MSCs		
		FBS	PL1	PL2	StdM	M1	M2
CD90	+ (≥95%)	+	+	+	↓	↑	nd
HLA-DR	- (≤2%)	-	↑	↑	-	-	nd
adipogenesis	+	+	+	+	↓	nd	nd
osteogenesis	+	+	+	+	↓	nd	nd
chondrogenesis	+	+	+	+	↓	nd	nd
immunosuppression	+	+	+	+	↑	↓	↓
angiogenic support	+	nd	nd	nd	↓	↑	↑

FBS=FBS containing medium, PL1= PL1 containing medium, PL2=PL2 containing medium

StdM = Standard growth medium, M1= Medium 1, M2=Medium 2

* ISCT criteria for human BM-MSCs cultured in FBS-medium (Dominici et al. 2006).

↑ = increased surface expression/ differentiation/functional capacity

↓ = decreased surface expression/differentiation/functional capacity

nd = no data

4.5 ADENOSINE PRODUCTION, ONE OF THE IMMUNOSUPPRESSIVE MECHANISMS OF MSCs

CD73 is one of the positive markers for MSCs included in the minimal criteria for MSCs (Dominici et al. 2006). As it is an ectonucleotidase that converts AMP into immunosuppressive Ado, its role as an immunosuppressive factor of MSCs was studied in this thesis. In the extracellular space, AMP is produced from ATP by another ectonucleotidase, CD39. Thus the expression of this molecule, along with CD73, was studied on MSCs and MSC-EVs, as well as on T cells, the targets of immunosuppressive action of MSCs. To connect the expression of CD73 to the immunosuppressive function of MSCs, the production of Ado was measured from MSC cultures and from the co-cultures of MSCs and T cells, and the impact of Ado on the proliferation of T cells was studied.

4.5.1 EXPRESSION OF CD73 AND CD39

The expression of CD73 and CD39 was studied by flow cytometric analysis and immunofluorescence microscopy. The results showed that CB- and BM-MSCs expressed CD73 on their cell surface (publication IV Figure 1H). CD39 expression could be detected on the surface of BM-MSCs, but not on CB-MSCs. In both cell types, intracellular expression of CD39 was detected and it co-localized with CD73 in filopodia and the bulge areas of cell membrane

(publication IV Figure 1). The positive labeling of CD73 was also seen on CB-MS-C-EVs (publication IV Figure 2B).

The expression of CD73 and CD39 on T cells was studied by flow cytometry after *in vitro* proliferation assay of these cells with or without the presence of MSCs in the assay. The expression of CD73 decreased significantly on T cells upon stimulation with CD3 and CD28 antibodies ($p < 0.05$ for CD4⁺ T cells and $p < 0.001$ for CD8⁺ T cells). On CD4⁺ T cells, the expression level of CD73 was low even without the stimulation, with about 10% of the cells being positive. The unstimulated CD8⁺ T cells expressed CD73 at a higher level, with about 72% of the cells being positive. The co-culture of stimulated T cells with MSCs significantly increased the expression of CD73 on both CD4⁺ and CD8⁺ T cells, compared to culture of stimulated T cells alone ($p < 0.001$ and $p < 0.01$, respectively). In CD4⁺ T cells, the expression of CD73 increased to a higher level than with unstimulated cells (publication IV Figure 6A).

The expression of CD39 increased significantly on both CD4⁺ and CD8⁺ T cells upon stimulation ($p < 0.05$ and $p < 0.01$, respectively). The co-culture with MSCs did not have an impact on CD39 expression of the stimulated T cells (publication IV Figure 6B).

4.5.2 THE PRODUCTION OF ADENOSINE

To study if the enzyme activity of CD73 molecule is seen on BM- and CB-MS-Cs, the production of Ado was studied by nucleotide measurements with HPLC from CM of MSC cultures supplemented with AMP or ATP. MSCs were capable of efficiently producing Ado from AMP but not from ATP. This production from AMP was inhibited dose dependently with CD73 inhibitor. The nucleotide measurements from CD3 enriched T cell cultures indicated that T cells produced AMP from ATP but could not produce any significant amounts of Ado (publication IV Figure 3A). Similarly to MSCs, CB-MS-C-EVs had the capacity to produce Ado from AMP but not to any great extent from ATP (publication IV Figure 3B), and this capacity was also blocked with CD73 inhibitor.

When stimulated T cells were combined with MSCs in the culture, Ado could be produced from ATP (publication IV Figure 3C). The stimulation of MSCs with cytokines did not significantly impact their capacity to produce Ado from ATP (publication IV Figure 4).

4.5.3 THE EFFECT OF ADENOSINE IN AN IMMUNOSUPPRESSION ASSAY

To assess if Ado has the capacity to suppress T cell proliferation in an *in vitro* assay, pure Ado was added into the culture of stimulated T cells. The results showed that the addition of Ado could dose dependently suppress T cell proliferation if the adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-

nonyl)adenine (EHNA), was also present in the assay (publication IV Figure 5A and B). A similar effect could not be detected without EHNA, indicating the presence of adenosine deaminase, which rapidly degrades Ado, in the assay.

To study if Ado plays a role in a four day co-culture assay of CB-MSCs and stimulated T cells, ATP was added to the assay with EHNA. In this assay, IDO is the predominant mechanism used by MSCs to suppress T cell proliferation. The addition of ATP to the co-culture in the presence of EHNA resulted in enhanced suppression of T cell proliferation, as compared to the suppressive effect of co-cultures without these additions. The effect was seen more clearly with CD8⁺ cells and in assays where the original suppressive capacity of MSCs was not very high (publication IV Figure 5C and D). Thus, it is likely that Ado production is one mechanism used by MSCs to suppress T cell proliferation.

5 DISCUSSION

5.1 THE ESTABLISHMENT OF EFFICIENT AND ROBUST CULTURE CONDITIONS FOR CB- AND BM-MSCs

MSCs are isolated and cultured from many different tissues (Caplan 1991; Erices et al. 2000; Friedenstein et al. 1976; Gronthos et al. 2000; in 't Anker et al. 2004; Wang et al. 2004; Zuk et al. 2002). As MSCs are only found in small numbers in the body they cannot just be collected and given directly to a patient. The *in vitro* culture of MSCs is an unavoidable step required to gain an adequate number of cells for research and clinical use. Thus, an efficient method to culture these cells is crucial when establishing the basis for clinical cell production.

For years, BM has been the standard source of MSCs, which have traditionally been thought to be part of the same general population, regardless of the tissue source. Comparative studies have, however, indicated clear differences between cells from different tissues (Chang et al. 2006b; Jin et al. 2013; Kern et al. 2006; Wagner et al. 2005) and thus it has been suggested that different MSC sources may generate MSC products suited to specific clinical applications (Horwitz and Dominici 2008).

In this thesis the aim was to investigate if there was a possibility to establish a method to increase the gain of MSCs from CB. The aim was also to establish a method to produce MSCs for clinical purposes. As BM is an easier material to produce MSCs and BM-MSCs have already been used in clinical studies, we compared two different GMP-compliant methods to produce clinically relevant numbers of BM-MSCs. The GMP-compliant medium efficient for BM-MSC culture was also tested for CB-MSC establishment, but it seemed not to be sufficient to obtain MSC from this source (data not shown). Thus, the GMP-compliant method to produce MSCs from CB still needs a lot of effort in further studies.

CB-MSCs

CB has been an attractive source due to its abundance and ease of access and the high proliferative capacity of the cells. But this source has turned out to be a difficult material to obtain MSCs from, with the success rate ranging from non-existing to 10%-63% (Bieback et al. 2004; Mareschi et al. 2001; Montesinos et al. 2009). Higher success rates have been gained only if the processing time has been kept to a minimum or units of a certain size have been used (Zhang et al. 2011). In this thesis, an efficient method to obtain MSCs from almost 90% of CB units is presented (publications I, II). This figure is considerably higher than the rates reported previously.

MSCs from CB seem to need more support for their *in vitro* growth than MSCs from BM. In our method for CB-MSCs, the supporting factors for these cells come in the form of growth factor-rich medium (StdM) containing EGF, PDGF, and DX in addition to FBS. The other important constituents contributing to the support of CB-MSC growth are FN-coated culture plates and an atmosphere with an O₂ concentration close to the physiological O₂ concentration, which is on average 3% on the tissue level (Haque et al. 2013).

Although we have established an efficient method for receiving MSCs from CB, plenty of further development is required before the method is GMP- and clinically-compliant. As using animal-derived components in cell culture always carries a risk of transmission of xenogeneic infectious agents and immunization (Cervenakova et al. 2011; Horwitz et al. 2002; Liu et al. 2008), the regulators urge the use of alternative supplements (EMA/CHMP/410869/2006 and EMA/410/01 rev.3). Thus, the first critical step is to replace FBS in the culture medium. As also the quality of biologically active additives, such as growth factors, needs to be tested and documented with respect to identity, purity, sterility, and biological activity of the components as well as for the absence of adventitious agents, the amount of work is tremendous if several components are included in the culture medium, as in StdM. Also, the practicality and financial aspects need to be considered when establishing culture methods.

BM-MSCs

BM seems to be an easier source in terms of obtaining and culturing MSCs than CB as MSC cultures can be established from every BM sample of good quality (Kern et al. 2006). BM-MSCs have also been the first MSCs used for clinical purposes even though the production of the MSCs has been based on FBS-containing medium (Horwitz et al. 2002; Lazarus et al. 1995; Le Blanc et al. 2004). In our studies, we compared two different GMP-compliant culture media (PL1 and PL2) based on platelet lysate against FBS-containing culture medium in regard to their capacity to support the growth of BM-MSCs (publication III). Based on these studies, we found the PL1-medium to be better suited to clinical production of MSCs as its production was more practical and it was superior in its MSC proliferation supporting ability. Thus we established our clinical BM-MSC manufacturing protocol based on this method.

Crucial factors in MSC culture

As a good cell yield is important when producing MSCs for clinical use, we analyzed the capacity of different cell culture conditions to support MSC proliferation. Another critical factor in *in vitro* cell culture, besides the composition of the medium, is the surrounding environment. Cells are

usually cultured in 5% CO₂ concentration, which reflects the CO₂ conditions *in vivo* (Csete 2005). The buffering capacity of the traditional culture media is optimized for use in this CO₂ concentration. The O₂ conditions are often ignored in tissue culture as the O₂ concentration is more complicated to regulate. However, the concentration of O₂ is important for virtually all cell processes (Csete 2005). In our studies, we produced evidence showing that low O₂ (3%) enhances the capacity of the MSCs to proliferate but this effect is more evident at late cell passages than in the early stages of culture (publications II, III). The combined effect of optimized culture medium and low O₂ gave the best results as the BM-MSCs cultured in PL1-supplemented medium in 3% O₂ concentration showed the shortest PD (publication III) time. Correspondingly, the CB-MSCs cultured in medium with the richest growth factor content (StdM) in 3% O₂ concentration reached the highest cumulative PD numbers in the shortest time (publication II). Although a positive influence of low O₂ concentration was seen in our studies, the impact of low O₂ was only minimal at the early passages of cell culture (publication III). For safety reasons, the method of choice for MSCs to be used for clinical purposes is to culture the cells *in vitro* for as short a time as possible (Wuchter et al. 2015) and therefore the O₂ concentration is not a critical factor when improving the cell yield in the early passages. In our studies, more impressive differences in the proliferative capacity of MSCs were seen between cells cultured in different media, with StdM being better than M1 for CB-MSCs and the PL1-medium being better compared to PL2 for BM-MSCs (publications II, III).

As expected, we found the growth factor-rich medium, StdM, to be more efficient in supporting the growth of CB-MSCs (publication II). The culture supplements EGF, PDGF, and DX have also been used by others to support cell growth (Reyes et al. 2001). The combination of PDGF and FN-coating of plastic-ware has been demonstrated to have a positive influence on the MSC proliferation (Veevers-Lowe et al. 2011). Veevers-Lowe et al. have shown that MSC adhesion to FN induces the $\alpha 5\beta 1$ -integrin (CD49e and CD29, both strongly expressed on MSCs) dependent phosphorylation of PDGF-receptor β (PDGFR- β). The adhesion to FN also strongly potentiates the PDGF-BB-induced phosphorylation of the receptor. This phosphorylation of PDGFR- β leads to downstream signal transduction, finally resulting in the stimulation of cell growth and motility as well as cell proliferation (Veevers-Lowe et al. 2011). EGF has been shown to maintain the colony forming capacity of MSCs, thus EGF helps to preserve early progenitors in MSC populations (Tamama et al. 2010). It has been indicated that DX increases proliferation, and the positive effect of DX at the beginning of CB-MSC culture may be a result of its inhibitory effect on monocytes adherence on culture plates (Roberts et al. 1998), thus allowing more space for MSCs to proliferate.

It could be speculated that the excess of growth factors may negatively affect MSC growth, for example shortening the life span of MSCs. However, in our studies we did not see any negative effect of growth factor rich

medium on CB-MSc growth, as MSCs in StdM reached higher population doubling numbers than MSCs in M1 medium. We also did not notice any abnormalities in the karyotype of CB-MSCs that were tested in early passages (passage 4) and at late passages (passage 14-16, data not shown). Nevertheless, to resolve if growth factor rich medium affects the stability of MSCs in other respect still needs further studies.

The two different PL supplements, PL1 and PL2, used in BM-MSc culture media, differed in their composition (Table 11) as PL2 was produced from PRP units and PL2 from platelet concentrates. The PL2 supplement was more concentrated and thus only a PL content of 0.5% was used in the final PL2-medium, compared to 10% PL1 supplement in PL1-medium, to have comparable numbers of lysed platelets between these supplements in final media. The PL1-supplement contained more AB-plasma, thus it was not necessary to add plasma to the PL1-medium. The plasma concentration of PL2-medium was lower although some AB-plasma was added to it. Another difference between these supplements was the number of freeze-thaw cycles applied, with PL2 being efficiently lysed with five cycles. Although the initial platelet counts of the supplements used to prepare the final media were comparable, the PL1 supplemented medium had better capacity to support MSC growth. It has been demonstrated that the freezing and thawing of PL has an effect on the growth factor composition of the supplement (Mojica-Henshaw et al. 2013) and consequently the high number of freeze-thaw cycles during the manufacture of PL2 may have inactivated some critical components in this supplement. Also the plasma content of medium has proved to be an important factor for cell proliferation (Horn et al. 2010).

Table 11. *Characteristics of the PL1 and PL2 supplements and their use in BM-MSc growth media (Modified from Laitinen et al. 2015, publication III Table 1)*

Supplement	COMPOSITION OF PLATELET UNITS/BAGS		PLATELET LYSATE				MSC GROWTH MEDIA		
	Description	Platelets x10 ⁹ *	Lysate additive	Lysed platelets x10 ⁹ /ml*	Freeze-thaw cycles	Pool size (nr of platelet units)	Concentration of platelet lysate (%)	Lysed platelets x10 ⁸ /ml*	Concentration of plasma (%)
PL1	Platelets in plasma, 4 donors BC	300	AB plasma	0.1	2	2-13	10	1.0	10
PL2	Platelets in 30% SSP/70% plasma, 4 donors BC	300	Octaplas AB (pooled virus-inactivated fresh frozen plasma)	15	5	15	0.5 (+ 2.5 % Octaplas AB)	0.8	3

*mean numbers
BC= buffy coat

5.2 IMPACT OF CULTURE CONDITIONS ON MSC CHARACTERISTICS AND FUNCTIONALITY

Although a good cell yield is the basis for producing cells for clinical use, it cannot override the quality and the properties of the cells. Culture conditions have been suggested to influence the properties of MSCs (Bieback et al. 2010; Roobrouck et al. 2011b; Wagner et al. 2005) and thus the impact of different culture conditions on cell properties should always be carefully examined. The possible alterations in the properties of MSCs can be observed by studying the phenotype or expression of certain molecules of the cells. Also, conducting several functional tests may help to elucidate the influence of culture conditions on cell properties. Any possible alterations in cellular phenotype are easily observed but the link between the expression of a particular molecule and a relevant function of MSCs is not usually known.

HLA-DR is one of the molecules that should not be expressed on the MSC cell surface according to the original minimal criteria to define MSCs (Dominici et al. 2006). This molecule is an example of how culture conditions may affect the phenotype. Certain inducing factors, such as IFN- γ and bFGF, have been shown to induce the expression of HLA-DR on MSCs (Le Blanc et al. 2003a; Romieu-Mourez et al. 2007; Sotiropoulou et al. 2006). Lately, the classification of this molecule as a negative marker for MSCs has been criticized as its expression is dependent on the culture conditions (Tarte et al. 2010). In our studies, HLA-DR expression levels differed depending on whether the BM-MSCs were cultured in PL1, PL2, or FBS-containing media (publication III). Although HLA-DR was expressed at different levels on these cells, the capacity of the cells to suppress T cell proliferation did not change in our *in vitro* assay. Others have also indicated that the expression of HLA-DR is not connected with the capacity of MSCs to inhibit T cell proliferation (Sotiropoulou et al. 2006; Tarte et al. 2010).

One MSC marker, for which variable expression was observed in our CB-MSC culture experiments when culturing the cells in different media, was CD90 (publication II). Its expression was decreased when culturing the cells in StdM, the growth factor-rich medium. Others have not reported the effects of growth factors on the expression of CD90 but the impact on other molecules, such as CD105 and CD146, has been reported (Gharibi and Hughes 2012). The connection between this marker and the functionality of MSCs is not been clearly demonstrated. A decrease in CD90 expression has been linked to the differentiation processes and diminished immunosuppressive capacities of MSCs (Sibov et al. 2012). In our experiments, functional consequences were not studied. There are also arguments against CD90 as a “specific” MSC marker as several groups have noticed only low-level expression of CD90 on CB-MSCs (Goodwin et al. 2001; Lee et al. 2004b; Montesinos et al. 2009; Nagano et al. 2010). Until a clear association between a particular phenotypic character and the functionality of MSCs is demonstrated, it cannot be concluded that a specific

phenotype leads to certain functional capacities of the cells and thus the functionality of MSCs should be somehow tested when altering culture conditions.

In our studies, the MSC batches obtained differed in their *HOX* gene expression pattern, which did not considerably change during passaging. This indicates heterogeneity in the cell populations obtained from individual CB units. Therefore, although the characteristics of MSCs can be influenced by culture conditions, there may be limitations as the initial culture conditions may eliminate some subtypes of cells from the MSC population. This was also proposed by Buchheiser et al. when they noted that culture conditions during cell generation may be more critical than temporary changes in O₂ concentrations and different cell populations may be generated at different frequencies depending on the O₂ concentration (Buchheiser et al. 2012).

It has been suggested that cell culture conditions could be modified to receive MSCs optimized for a specific clinical indication (Horwitz and Dominici 2008). In our studies, we show that culture conditions have an effect on the functionality of MSCs *in vitro*. With CB-MSCs, we demonstrated that although StdM, the growth factor-rich medium, had the greater ability to support the growth of MSCs, its ability to promote the angiogenic supporting capacity of MSCs was diminished, as MSCs cultured in this medium expressed VEGF mRNA at a lower level than cells cultured in medium containing less growth factors and without DX, M1, and M2 media. MSCs induced in different media and then transferred into similar conditions still showed divergent potential to produce VEGF and to support angiogenesis in an *in vitro* tubule formation assay (publication II). This demonstrates the inductive impact of culture conditions to influence the angiogenic capacity of MSCs. On the other hand, our experiments showed that MSCs cultured in the presence of DX had a greater capacity to suppress T cell proliferation in an *in vitro* T cell proliferation assay (publication II). Thus when optimizing the culture conditions, for instance, to achieve higher cell yields, one should bear in mind that the changes in culture conditions may have an effect on the functionality of the cells, which is not always seen simply as alterations in the phenotype of the cells.

Another indication of culture conditions having an impact on the functionality of MSCs was seen in our experiment aimed at differentiating BM-MSCs into osteoblasts (publication III). When MSCs were initially cultured in PL1-containing medium their capacity to differentiate into bone forming osteoblasts was diminished if the differentiation was performed in traditional FBS-containing differentiation medium. When the differentiation was performed in PL1-containing medium the differentiation was much more pronounced. The adipogenic differentiation of the CB-MSCs also suggested that by altering the adipogenic differentiation medium, the CB-MSCs could be differentiated into adipocytes with increased frequency (publication II). The adipogenic differentiation of CB-MSCs has been demonstrated to be

weak (Bieback et al. 2004; Chang et al. 2006b; Manca et al. 2008; Yoshioka et al. 2015; Zhang et al. 2011). In our studies, the adipogenic differentiation was also shown to be very weak if the traditional differentiation medium was used. When the differentiation medium was optimized for CB-MSCs by using the PPAR γ ligand, ciglitazone, the adipogenic differentiation was enhanced.

5.3 ADENOSINE PRODUCTION AS AN IMMUNOSUPPRESSIVE MECHANISM OF MSCs

MSCs have demonstrated to have many mechanisms to suppress immune reactions (Castro-Manrreza and Montesinos 2015). In this thesis, a relatively unknown immunosuppressive mechanism of MSCs via adenosinergic signalling is presented.

We became interested in the CD73 molecule, an ectonucleotidase that converts AMP into a highly immunosuppressive purine nucleoside Ado, as the anti-CD73 antibody was one of the few antibodies produced in our experiments of whole cell immunizations of the mice (unpublished data in collaboration with Medix Biochemica). This CD73 molecule is constantly expressed on MSCs at high intensity. The immunosuppressive effects of CD73 have been demonstrated with Tregs, tumor cells, and recently with MSCs (Amarnath et al. 2015; Chen et al. 2013; Chen et al. 2016; Deaglio et al. 2007; Ghiringhelli et al. 2012; Sattler et al. 2011). In our studies, we explored the capacity of MSCs to suppress T cell proliferation in an *in vitro* assay and our aim was to demonstrate the role of Ado in the MSC mediated T cell suppression (publication IV).

The expression of CD73 was noted to differ between individual cell batches, but we did not notice any effect of the different culture conditions on the capacity of MSCs to express CD73. Interestingly the co-expression of CD73 and CD39 was observed in filopodia and the bulge areas of cell membrane, indicating the possibility that MSCs may have the capacity to transfer CD39 to their cell surface under certain stimuli, as demonstrated by others in a co-culture assay of MSCs and T cells (Saldanha-Araujo et al. 2011).

Using HPLC analysis, we saw that BM- and CB-MSCs and CB-MSC-EVs could efficiently produce Ado only from AMP. From ATP this was possible only if stimulated T cells were present together with MSCs in the assay, indicating that MSCs act synergistically with immune cells to produce immunosuppressive Ado in conditions containing ATP. As the Ado production was inhibited by CD73 inhibitor we could conclude that CD73 has a critical role in the production of Ado by MSCs. Though we saw the impact of CD73 inhibitor in the short time co-culture assays with HPLC analysis, we could not demonstrate its impact in our four day *in vitro* co-culture assay.

The immunosuppressive impact of MSCs in the *in vitro* T cell suppression assay comes mainly from the effects of MSC-produced IDO as its inhibition

restores the proliferative capacity of T cells. This has also been demonstrated by others (Francois et al. 2012; Jones et al. 2007; Menard et al. 2013). Although the suppressive capacity of MSCs in the assay was mainly due to the action of IDO we could, however, see improvement in the suppressive impact of MSCs when the cultures were supplemented with ATP and adenosine deaminase inhibitor, EHNA, to stabilize the produced Ado. Even though the promoting effect of the adenosinergic pathway on the suppression of T cells was not outstanding in this assay, it indicated the Ado route as one of the mechanisms used by MSCs to suppress T cell proliferation.

As *in vitro* assays are artificial with several additives that need to be added to co-cultures the conditions never truly resemble the situation *in vivo*. Therefore it is difficult to demonstrate the immunosuppressive mechanisms of MSCs in a co-culture assay and to predict their true *in vivo* capacities. The suppressive effect of Ado has been demonstrated with an *in vivo* mouse GVHD-model and autoimmune uveitis model, as blocking Ado-receptor with a receptor antagonist or blocking CD73 with CD73 inhibitor abrogated the ability of MSCs to suppress the inflammatory effects of T cells (Amarnath et al. 2015; Chen et al. 2016). Thus, adenosinergic pathway seems to be one relevant mechanism of MSCs to suppress immune reactions.

In our studies, we also explored the expression of CD73 and CD39 on T cells in the *in vitro* T cell suppression assay. The capacity of MSCs to increase the expression of CD73 on stimulated T cells was significant. Similar impacts by MSCs on the CD73 expression on T cells have been demonstrated by others (Chen et al. 2016; Saldanha-Araujo et al. 2011). This indicates the role of MSCs to prime T cells to express CD39 and CD73, which both are needed for Ado production. TGF- β has been introduced to act as an agent by which MSCs up-regulate the expression of CD73 on T cells (Chen et al. 2016). In our studies, we showed that also MSC-EVs are CD73 positive and thus it is intriguing to hypothesize that the CD73 positivity of T cells might be mediated by CD73 positive EVs. Whether EVs mediate the expression of CD73 on T cells or not, they still offer an active enzyme to enable the production of Ado via CD39 and CD73 molecules.

As natural Tregs are described as being positive for CD39 but negative for CD73, they would need assistance from neighboring CD73 positive cells or EVs to produce Ado. *In vitro* induced Tregs, on the other hand, are described as being positive for CD73, and therefore capable of producing Ado on their own (Whiteside et al. 2011). Our results indicated that the expression of CD73 increased on T cells in the presence of MSCs, but we did not specifically determine whether the number of Tregs had increased. CD8⁺ T cells expressed higher levels of both CD39 and CD73, thus pointing to the adenosinergic pathway being important also for other cell populations and not just for CD4⁺CD25⁺ Tregs. In any case, as our results showed, the overall capacity of stimulated T cell populations to produce Ado from ATP increases in the presence of MSCs as both adenosinergic pathway enzymes are present. This adenosinergic pathway might be a relevant mechanism for

MSCs to suppress immune cell reactions especially in tissue damage, where ATP is abundantly available and since MSCs have the capacity to home into areas of injury and inflammation.

5.4 CONCLUDING REMARKS AND FUTURE PERSPECTIVES

In this thesis, it was demonstrated that MSCs can be efficiently cultured from CB though this material is not as reliable as a source of MSCs as BM. Succeeding in obtaining MSCs from CB requires more from the culture conditions than to obtaining MSCs from BM. In this thesis, it was shown that many different growth factors, along with low oxygen concentration, were needed to efficiently obtain MSCs from CB. And as each additive in the culture medium should be of GMP-grade, the development of a GMP-compliant CB-MSC production method still needs a considerable amount of effort. For BM-MSCs, one robust GMP-compliant culture method is presented in this thesis.

The culture conditions of MSCs have impact on both the proliferative capacity of MSCs and the functional capacities of these cells. In this thesis, the impact of different culture media on the functional capacity of CB-MSCs to support angiogenesis and their capacity to suppress T cell proliferation was demonstrated. Similarly, the culture conditions certainly impact the functionality of MSCs from other sources.

Many mechanisms for MSCs to produce their therapeutic effects have been presented. In this thesis, the Ado producing capacity of MSCs is demonstrated to be a novel mechanisms used by these cells to suppress T cell proliferation. As MSCs are capable of producing Ado from ATP in cooperation with T cells and as the level of ATP is usually high in situations such as tissue damage, this mechanism may be a crucial factor influencing the therapeutic effects of these cells in tissue damage indications. Extensive research is still required to elucidate, how the Ado producing mechanism, as well as other functional mechanisms of MSCs, operate *in vitro* and whether a particular mechanism is more important in a certain indication. If the importance of these mechanisms could be linked to the therapeutic outcomes of different MSC treatments, it might be possible to tailor specific MSCs for each indication, possibly by merely optimizing the culture conditions for the MSCs. Also, *in vitro* functional tests to determine the true *in vivo* potential of MSCs must be developed to ensure that the cells given to a patient are functional for that particular purpose.

ACKNOWLEDGEMENTS

This study was carried out at the Finnish Red Cross Blood Service in Helsinki. This study was financially supported by the Finnish Red Cross Blood Service, state research funding (EVO grants) and by the SalWe Research Programs for IMO and GET IT DONE (Tekes - the Finnish Funding Agency for Technology and Innovation grants 648/10 and 534/14).

I am grateful for the Chief Executive of the Blood Service, adj. prof Martti Syrjälä, as well as the former chief executives, and the present and former directors of the Research and Development unit, adj. prof Kari Aranko, adj. prof Jaana Mättö, and Professor Jukka Partanen for providing excellent working facilities and for creating the research-positive atmosphere. I also wish to express my gratitude to my initial supervisor Dr Jarmo Laine who introduced me to this field.

My sincere and warm thanks go to my supervisors, adj. prof. Johanna Nystedt and Dr Saara Laitinen. Saara being my main supervisor at the early years of this thesis project with so many inspiring ideas. And Johanna, being the promoter for me to finalize this thesis project, arranging the time and facilities for me to do it.

I thank the reviewers of this thesis, Professor Wolfgang Wagner and Dr Lorenza Lazzari, for their time and careful revision of this thesis.

I also warmly thank the thesis committee members, adj. prof. Pia Siljander and adj. prof. Esko Kankuri, for their encouraging comments through the last years of this thesis project.

All the co-authors of the accompanying publications are acknowledged for the professional co-operation. Especially I want to thank adj. prof. Erja Kerkelä for sharing her knowledge and enthusiasm on immunosuppressive mechanisms of MSCs. I acknowledge adj. prof Matti Korhonen for his excellent comments, Lotta Kilpinen for always finding an answer to my questions and, Dr Milla Lampinen, Sofia Oja and Tanja Kaartinen for the valuable work done to produce the data in the accompanying publications.

I also want to thank the excellent technical staff of R&D and Advanced cell therapy centre (STK), Sirkka, Iris, Lotta S., Lotta A., Gitta, and Sisko for their contribution to the laboratory work of the publications presented in this thesis and also all the other people in the laboratory making the working in there so pleasant. I also thank all the former and present people in the

Acknowledgements

departments of R&D and STK for the relaxing company at lunch and coffee breaks.

I acknowledge Marja-Leena Hyvönen for the library services and Piia Lopenen and Pirjo Nick for the professional secretarial support. I also thank Niina Woolley for the revision of the language of this thesis.

My warmest thanks go to my family. My parents, Tuula and Jarmo, without them this thesis would not have happened, they have helped me so much, especially with the kids. I am grateful to my sisters, Leena and Kati for helping me in so many ways. My dearest thanks are reserved to my beloved husband Pauli for all the support and encouragement and my kids, Vilho, Valto and Eeva, you give me the strength to go on.

Helsinki, June 2016

Anita Laitinen

REFERENCES

- Ackema KB, Charite J (2008) Mesenchymal stem cells from different organs are characterized by distinct topographic Hox codes. *Stem Cells Dev* 17:979-991
- Adjei IM, Blanka S (2015) Modulation of the tumor microenvironment for cancer treatment: a biomaterials approach. *J Funct Biomater* 6:81-103
- Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 105:1815-1822
- Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S (2012) Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. *Cell Stem Cell* 10:544-555
- Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles ME, Diaz-Rodriguez E, Garcia-Rendueles AR, Perez-Romero S, Vila TV, Rodrigues JS, Lear PV, Bravo SB (2012) Defining stem cell types: understanding the therapeutic potential of ESCs, ASCs, and iPS cells. *J Mol Endocrinol* 49:R89-111
- Alvarez-Dolado M, Pardo R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, Alvarez-Buylla A (2003) Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. *Nature* 425:968-973
- Amarnath S, Foley JE, Farthing DE, Gress RE, Laurence A, Eckhaus MA, Metais JY, Rose JJ, Hakim FT, Felizardo TC, Cheng AV, Robey PG, Stroncek DE, Sabatino M, Battiwalla M, Ito S, Fowler DH, Barrett AJ (2015) Bone marrow-derived mesenchymal stromal cells harness purinergic signaling to tolerize human Th1 cells in vivo. *Stem Cells* 33:1200-1212
- Ancans J (2012) Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. *Front Immunol* 3:253
- Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: immune evasive, not immune privileged. *Nat Biotechnol* 32:252-260
- Aranha AM, Zhang Z, Neiva KG, Costa CA, Hebling J, Nor JE (2010) Hypoxia enhances the angiogenic potential of human dental pulp cells. *J Endod* 36:1633-1637
- Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S, Ohgushi H (2010) Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. *Cytotherapy* 12:265-268
- Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Agnor EN, Timmers L, van Rijen HV, Doevendans PA, Pasterkamp G, Lim SK, de Kleijn DP (2013)

References

- Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. *Stem Cell Res* 10:301-312
- Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *Eur J Immunol* 35:1482-1490
- Bang OY, Lee JS, Lee PH, Lee G (2005) Autologous mesenchymal stem cell transplantation in stroke patients. *Ann Neurol* 57:874-882
- Bara JJ, Richards RG, Alini M, Stoddart MJ (2014) Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. *Stem Cells* 32:1713-1723
- Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, Doody M, Venter D, Pain S, Gilshenan K, Atkinson K (2008) Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. *Stem Cells Dev* 17:1095-1107
- Bekhte MM, Finkensieper A, Rebhan J, Huse S, Schultze-Mosgau S, Figulla HR, Sauer H, Wartenberg M (2014) Hypoxia, leptin, and vascular endothelial growth factor stimulate vascular endothelial cell differentiation of human adipose tissue-derived stem cells. *Stem Cells Dev* 23:333-351
- Bersenev A (2015) Trends in cell therapy clinical trials 2011 – 2014. <http://celltrials.info/2015/02/14/trends-2014/>
- Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* 105:2214-2219
- Bieback K, Ha VA, Hecker A, Grassl M, Kinzebach S, Solz H, Sticht C, Kluter H, Bugert P (2010) Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. *Tissue Eng Part A* 16:3467-3484
- Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. *Stem Cells* 27:2331-2341
- Bieback K, Kern S, Kluter H, Eichler H (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. *Stem Cells* 22:625-634
- Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, DiMattia G, Sullivan DE, Prockop DJ (2009) Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. *Stem Cells* 27:670-681

Boomsma RA, Geenen DL (2012) Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. *PLoS One* 7:e35685

Borea PA, Gessi S, Merighi S, Varani K (2016) Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?. *Trends Pharmacol Sci* 37:419-434

Both SK, van der Muijsenberg AJ, van Blitterswijk CA, de Boer J, de Bruijn JD (2007) A rapid and efficient method for expansion of human mesenchymal stem cells. *Tissue Eng* 13:3-9

Bronckaers A, Hilkens P, Martens W, Gervois P, Ratajczak J, Struys T, Lambrechts I (2014) Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. *Pharmacol Ther* 143:181-196

Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD, Mezey E (2011) Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. *Clin Exp Allergy* 41:526-534

Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G (2009) Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol* 20:1053-1067

Buchheiser A, Houben AP, Bosch J, Marbach J, Liedtke S, Kogler G (2012) Oxygen tension modifies the 'stemness' of human cord blood-derived stem cells. *Cytotherapy* 14:967-982

Buckler RL, Kunkel EJ, Thompson ML, Ehrhardt RO (2016) Technological developments for small-scale downstream processing of cell therapies. *Cytotherapy* 18:301-306

Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. *Pharmacol Rev* 58:58-86

Caplan AI, Correa D (2011) The MSC: an injury drugstore. *Cell Stem Cell* 9:11-15

Caplan AI (2008) All MSCs are pericytes?. *Cell Stem Cell* 3:229-230

Caplan AI (1991) Mesenchymal stem cells. *J Orthop Res* 9:641-650

Carrancio S, Lopez-Holgado N, Sanchez-Guijo FM, Villaron E, Barbado V, Tabera S, Diez-Campelo M, Blanco J, San Miguel JF, Del Canizo MC (2008) Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. *Exp Hematol* 36:1014-1021

Castro-Manreza ME, Montesinos JJ (2015) Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. *J Immunol Res* 2015:394917

References

- Celis P, Ferry N, Hystad M, Schussler-Lenz M, Doevendans PA, Flory E, Beuneu C, Reischl I, Salmikangas P (2015) Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014. *Transfus Med Hemother* 42:194-199
- Cervenakova L, Akimov S, Vasilyeva I, Yakovleva O, McKenzie C, Cervenak J, Piccardo P, Asher DM (2011) Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects murine bone marrow-derived cells with features of mesenchymal stem cells. *Transfusion* 51:1755-1768
- Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Souillou JP, Anegon I, Cuturi MC (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. *Blood* 110:3691-3694
- Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, Yen BL (2006a) Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. *Stem Cells* 24:2466-2477
- Chang YJ, Huang XJ (2013) Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?. *Blood Rev* 27:55-62
- Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM (2006b) Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. *Stem Cells* 24:679-685
- Charbord P (2010) Bone marrow mesenchymal stem cells: historical overview and concepts. *Hum Gene Ther* 21:1045-1056
- Chen L, Tredget EE, Wu PY, Wu Y (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. *PLoS One* 3:e1886
- Chen M, Su W, Lin X, Guo Z, Wang J, Zhang Q, Brand D, Ryffel B, Huang J, Liu Z, He X, Le AD, Zheng SG (2013) Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. *Arthritis Rheum* 65:1181-1193
- Chen SL, Fang WW, Qian J, Ye F, Liu YH, Shan SJ, Zhang JJ, Lin S, Liao LM, Zhao RC (2004) Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. *Chin Med J (Engl)* 117:1443-1448
- Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK (2010) Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. *Nucleic Acids Res* 38:215-224

Chen X, Shao H, Zhi Y, Xiao Q, Su C, Dong L, Liu X, Li X, Zhang X (2016) CD73 Pathway Contributes to the Immunosuppressive Ability of Mesenchymal Stem Cells in Intraocular Autoimmune Responses. *Stem Cells Dev* 25:337-346

Cho DI, Kim MR, Jeong HY, Jeong HC, Jeong MH, Yoon SH, Kim YS, Ahn Y (2014) Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. *Exp Mol Med* 46:e70

Colter DC, Class R, DiGirolamo CM, Prockop DJ (2000) Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. *Proc Natl Acad Sci U S A* 97:3213-3218

Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badyrak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 3:301-313

Csete M (2005) Oxygen in the cultivation of stem cells. *Ann N Y Acad Sci* 1049:1-8

da Silva Meirelles L, Caplan AI, Nardi NB (2008) In search of the in vivo identity of mesenchymal stem cells. *Stem Cells* 26:2287-2299

da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. *Cytokine Growth Factor Rev* 20:419-427

Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E (2015) Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. *Front Immunol* 6:605

de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A (2013) Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. *Int J Colorectal Dis* 28:313-323

De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N (2011) Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. *J Cell Physiol* 226:2131-2138

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 204:1257-1265

Dehkordi MB, Madjd Z, Chaleshtori MH, Meshkani R, Nikfarjam L, Kajbafzadeh A (2015) A Simple, Rapid, and Efficient Method for Isolating Mesenchymal Stem Cells from the Entire Umbilical Cord. *Cell Transplant*

References

- Delarosa O, Dalemans W, Lombardo E (2012) Toll-like receptors as modulators of mesenchymal stem cells. *Front Immunol* 3:182
- Deo SS, Gottlieb DJ (2015) Adoptive T-cell therapy for fungal infections in haematology patients. *Clin Transl Immunology* 4:e40
- Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S, Ide C, Nabeshima Y (2005) Bone marrow stromal cells generate muscle cells and repair muscle degeneration. *Science* 309:314-317
- D'Ippolito G, Diabira S, Howard GA, Roos BA, Schiller PC (2006) Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. *Bone* 39:513-522
- D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC (2004) Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. *J Cell Sci* 117:2971-2981
- Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noel D (2007) Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. *Stem Cells* 25:2025-2032
- Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D (2006) Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. *Transplantation* 82:1060-1066
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 8:315-317
- Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, da Silva CL, Cabral JM (2010) Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. *J Cell Physiol* 223:27-35
- Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. *Gut* 59:1662-1669
- Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. *Blood* 99:3916-3922

- English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP (2009) Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. *Clin Exp Immunol* 156:149-160
- Erices A, Conget P, Minguell JJ (2000) Mesenchymal progenitor cells in human umbilical cord blood. *Br J Haematol* 109:235-242
- Estrada JC, Albo C, Benguria A, Dopazo A, Lopez-Romero P, Carrera-Quintanar L, Roche E, Clemente EP, Enriquez JA, Bernad A, Samper E (2012) Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. *Cell Death Differ* 19:743-755
- Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292:154-156
- Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shryer D, Carson P (2007) Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. *Tissue Eng* 13:1299-1312
- Fang B, Song Y, Liao L, Zhang Y, Zhao RC (2007) Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. *Transplant Proc* 39:3358-3362
- Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, Gully C, Gassner R, Lepperdinger G (2007) Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. *Aging Cell* 6:745-757
- Francois M, Romieu-Mourez R, Li M, Galipeau J (2012) Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. *Mol Ther* 20:187-195
- Friedenstein AJ, Gorskaja JF, Kulagina NN (1976) Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 4:267-274
- Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation* 6:230-247
- Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 169:12-20
- Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Arriero Mdel M, Lassaletta A, Madero L, Ramirez M (2010) Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. *Cancer Gene Ther* 17:476-483

References

- Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA (2005) A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis Colon Rectum* 48:1416-1423
- Gharibi B, Hughes FJ (2012) Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. *Stem Cells Transl Med* 1:771-782
- Ghiringhelli F, Bruchard M, Chalmin F, Rebe C (2012) Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. *J Biomed Biotechnol* 2012:473712
- Gill S, Maus MV, Porter DL (2016) Chimeric antigen receptor T cell therapy: 25years in the making. *Blood Rev* 30:157-167
- Gimble J, Guilak F (2003) Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy* 5:362-369
- Glenn JD, Whartenby KA (2014) Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. *World J Stem Cells* 6:526-539
- Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA (2001) Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. *Biol Blood Marrow Transplant* 7:581-588
- Gould SJ, Raposo G (2013) As we wait: coping with an imperfect nomenclature for extracellular vesicles. *J Extracell Vesicles* 2:10.3402/jev.v2i0.20389
- Grange C, Tapparo M, Bruno S, Chatterjee D, Quesenberry PJ, Tetta C, Camussi G (2014) Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. *Int J Mol Med* 33:1055-1063
- Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S (2000) Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci U S A* 97:13625-13630
- Guo T, Chamoto K, Hirano N (2015) Adoptive T Cell Therapy Targeting CD1 and MR1. *Front Immunol* 6:247
- Haque N, Rahman MT, Abu Kasim NH, Alabsi AM (2013) Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. *ScientificWorldJournal* 2013:632972
- Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Jr, Reisman MA, Schaer GL, Sherman W (2009) A randomized, double-blind, placebo-controlled, dose-

escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol* 54:2277-2286

Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 9:12-811X-9-12

Ho AD, Wagner W, Franke W (2008) Heterogeneity of mesenchymal stromal cell preparations. *Cytotherapy* 10:320-330

Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, Waxman SG, Kocsis JD (2011) Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. *Brain* 134:1790-1807

Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C, Drescher W, Hutschenreuther G, Zenke M, Ho AD, Wagner W (2010) Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. *Cytotherapy* 12:888-898

Horwitz EM, Dominici M (2008) How do mesenchymal stromal cells exert their therapeutic benefit?. *Cytotherapy* 10:771-774

Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* 7:393-395

Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci U S A* 99:8932-8937

Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S (2007) New advances in iPS cell research do not obviate the need for human embryonic stem cells. *Cell Stem Cell* 1:367-368

in 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GMJS, Claas FHJ, Fibbe WE, Kanhai HHH (2004) Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta. *Stem Cells* 22:1338-1345

Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S (2016) Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles. *Int J Mol Sci* 17:171

Ji P, Manupipatpong S, Xie N, Li Y (2016) Induced Pluripotent Stem Cells: Generation Strategy and Epigenetic Mystery behind Reprogramming. *Stem Cells Int* 2016:8415010

References

- Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM (2002) Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. *Exp Hematol* 30:896-904
- Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, Kim SW, Yang YS, Oh W, Chang JW (2013) Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. *Int J Mol Sci* 14:17986-18001
- Jones BJ, Brooke G, Atkinson K, McTaggart SJ (2007) Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. *Placenta* 28:1174-1181
- Juhl M, Tratwal J, Follin B, Sondergaard RH, Kirchhoff M, Ekblond A, Kastrup J, Haack-Sorensen M (2016) Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue. *Scand J Clin Lab Invest* 76:93-104
- Julavijitphong S, Wichitwiengrat S, Tirawanchai N, Ruangvutilert P, Vantanasiri C, Phermthai T (2014) A xeno-free culture method that enhances Wharton's jelly mesenchymal stromal cell culture efficiency over traditional animal serum-supplemented cultures. *Cytotherapy* 16:683-691
- Jung KW (2009) Perspectives on human stem cell research. *J Cell Physiol* 220:535-537
- Jung S, Sen A, Rosenberg L, Behie LA (2010) Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. *Cytotherapy* 12:637-657
- Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, Ringden O (2012) Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. *Clin Exp Immunol* 167:543-555
- Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Arch Neurol* 67:1187-1194
- Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. *Biol Blood Marrow Transplant* 15:804-811
- Kerkela E, Hakkarainen T, Makela T, Raki M, Kambur O, Kilpinen L, Nikkila J, Lehtonen S, Ritamo I, Pernu R, Pietila M, Takalo R, Juvonen T, Bergstrom K, Kalso E, Valmu L, Laitinen S, Lehenkari P, Nystedt J (2013) Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. *Stem Cells Transl Med* 2:510-520

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K (2006) Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 24:1294-1301

Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. *Eur J Gastroenterol Hepatol* 21:1199-1205

Kilpinen L, Impola U, Sankkila L, Ritamo I, Aatonen M, Kilpinen S, Tuimala J, Valmu L, Levijoki J, Finckenberg P, Siljander P, Kankuri E, Mervaala E, Laitinen S (2013) Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. *J Extracell Vesicles* 2:10.3402/jev.v2i0.21927. eCollection 2013

Kim HY, Kim H, Oh KW, Oh SI, Koh SH, Baik W, Noh MY, Kim KS, Kim SH (2014) Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study. *Stem Cells* 32:2724-2731

Kim J, Hematti P (2009) Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. *Exp Hematol* 37:1445-1453

Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J (2007) Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. *Cell Physiol Biochem* 20:867-876

Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* 94:678-685

Kluth SM, Buchheiser A, Houben AP, Geyh S, Krenz T, Radke TF, Wiek C, Hanenberg H, Reinecke P, Wernet P, Kogler G (2010) DLK-1 as a marker to distinguish unrestricted somatic stem cells and mesenchymal stromal cells in cord blood. *Stem Cells Dev* 19:1471-1483

Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W (2002) Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). *Bone Marrow Transplant* 30:215-222

Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Muller HW, Zanjani E, Wernet P (2004) A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. *J Exp Med* 200:123-135

References

- Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doepfner TR, Epple M, Horn PA, Beelen DW, Giebel B (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. *Leukemia* 28:970-973
- Kucia M, Reza R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, Ratajczak MZ (2006) A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. *Leukemia* 20:857-869
- Kuo CK, Tuan RS (2008) Mechanoactive tenogenic differentiation of human mesenchymal stem cells. *Tissue Eng Part A* 14:1615-1627
- Laitinen A, Laine J (2007) Isolation of mesenchymal stem cells from human cord blood. *Curr Protoc Stem Cell Biol Chapter 2:Unit 2A.3*
- Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ, Canadian Critical Care Trials Group (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PLoS One* 7:e47559
- Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI (1995) Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. *Bone Marrow Transplant* 16:557-564
- Le Blanc K, Frasson F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O, Developmental Committee of the European Group for Blood and Marrow Transplantation (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* 371:1579-1586
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 363:1439-1441
- Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O (2003a) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 31:890-896
- Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003b) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol* 57:11-20
- Lee JJ, Jeong HJ, Kim MK, Wee WR, Lee WW, Kim SU, Sung C, Yang YH (2014) CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. *Purinergic Signal* 10:357-365

Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY, STARTING collaborators (2010) A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *Stem Cells* 28:1099-1106

Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK (2004a) In vitro hepatic differentiation of human mesenchymal stem cells. *Hepatology* 40:1275-1284

Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH (2004b) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood* 103:1669-1675

Lennon DP, Schluchter MD, Caplan AI (2012) The effect of extended first passage culture on the proliferation and differentiation of human marrow-derived mesenchymal stem cells. *Stem Cells Transl Med* 1:279-288

Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W (2013) Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev* 22:845-854

Liang J, Zhang H, Wang D, Feng X, Wang H, Hua B, Liu B, Sun L (2012) Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. *Gut* 61:468-469

Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. *Ann Rheum Dis* 69:1423-1429

Liedtke S, Buchheiser A, Bosch J, Bosse F, Kruse F, Zhao X, Santourlidis S, Kogler G (2010) The HOX Code as a "biological fingerprint" to distinguish functionally distinct stem cell populations derived from cord blood. *Stem Cell Res* 5:40-50

Lindroos B, Suuronen R, Miettinen S (2011) The potential of adipose stem cells in regenerative medicine. *Stem Cell Rev* 7:269-291

Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V, Santarlasci V, Consoloni L, Angelotti ML, Romagnani P, Parronchi P, Krampera M, Maggi E, Romagnani S, Annunziato F (2008) Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. *Stem Cells* 26:279-289

Liu C, Fan Y, Zhou L, Zhu HY, Song YC, Hu L, Wang Y, Li QP (2015) Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction. *Int J Cardiol* 188:22-32

References

- Liu L, Xia H, Belak S, Baule C (2008) A TaqMan real-time RT-PCR assay for selective detection of atypical bovine pestiviruses in clinical samples and biological products. *J Virol Methods* 154:82-85
- Llufriu S, Sepulveda M, Blanco Y, Marin P, Moreno B, Berenguer J, Gabilondo I, Martinez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernandez B, Bullich S, Sanchez-Dalmau B, Graus F, Villoslada P, Saiz A (2014) Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. *PLoS One* 9:e113936
- Lv FJ, Tuan RS, Cheung KM, Leung VY (2014) Concise review: the surface markers and identity of human mesenchymal stem cells. *Stem Cells* 32:1408-1419
- Macmillan ML, Blazar BR, DeFor TE, Wagner JE (2009) Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. *Bone Marrow Transplant* 43:447-454
- Madrigal M, Rao KS, Riordan NH (2014) A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. *J Transl Med* 12:260-014-0260-8
- Mahmood A, Lu D, Lu M, Chopp M (2003) Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. *Neurosurgery* 53:697-702; discussion 702-3
- Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest* 103:697-705
- Manca MF, Zwart I, Beo J, Palasingham R, Jen LS, Navarrete R, Girdlestone J, Navarrete CV (2008) Characterization of mesenchymal stromal cells derived from full-term umbilical cord blood. *Cytotherapy* 10:54-68
- Mantia-Smaldone GM, Chu CS (2013) A review of dendritic cell therapy for cancer: progress and challenges. *BioDrugs* 27:453-468
- Mareschi K, Biasin E, Piacibello W, Aglietta M, Madon E, Fagioli F (2001) Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. *Haematologica* 86:1099-1100
- Mason C, Brindley DA, Culme-Seymour EJ, Davie NL (2011) Cell therapy industry: billion dollar global business with unlimited potential. *Regen Med* 6:265-272
- Mattar P, Bieback K (2015) Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells. *Front Immunol* 6:560

Maumus M, Peyrafitte JA, D'Angelo R, Fournier-Wirth C, Bouloumie A, Casteilla L, Sengenès C, Bourin P (2011) Native human adipose stromal cells: localization, morphology and phenotype. *Int J Obes (Lond)* 35:1141-1153

Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E (2003) Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. *Amyotroph Lateral Scler Other Motor Neuron Disord* 4:158-161

Mead B, Berry M, Logan A, Scott RA, Leadbeater W, Scheven BA (2015) Stem cell treatment of degenerative eye disease. *Stem Cell Res* 14:243-257

Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood* 103:4619-4621

Menard C, Pacelli L, Bassi G, Dulong J, Bifari F, Bezier I, Zanoncello J, Ricciardi M, Latour M, Bourin P, Schrezenmeier H, Sensebe L, Tarte K, Krampera M (2013) Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. *Stem Cells Dev* 22:1789-1801

Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, Dorval C, Martiat P, Lewalle P, Lagneaux L, Bron D (2009) Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. *Stem Cells Dev* 18:1247-1252

Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R (2007) Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. *Arch Iran Med* 10:459-466

Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, Sanatkar M, Gasemi M, Mirkhani H, Radmehr H, Salehi M, Eslami M, Farhig-Parsa A, Emami-Razavi H, Alemohammad MG, Solimani AA, Ghavamzadeh A, Nikbin B (2007) Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. *Arch Iran Med* 10:467-473

Mojica-Henshaw MP, Jacobson P, Morris J, Kelley L, Pierce J, Boyer M, Reems JA (2013) Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures. *Cytotherapy* 15:1458-1468

Mokarizadeh A, Delirez N, Morshedi A, Mosayebi G, Farshid AA, Mardani K (2012) Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. *Immunol Lett* 147:47-54

Montesinos JJ, Flores-Figueroa E, Castillo-Medina S, Flores-Guzman P, Hernandez-Estevez E, Fajardo-Orduna G, Orozco S, Mayani H (2009) Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their

References

morphology, immunophenotype, differentiation patterns and neural protein expression. *Cytotherapy* 11:163-176

Munir H, McGettrick HM (2015) Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards. *Stem Cells Dev* 24:2091-2100

Nagano M, Kimura K, Yamashita T, Ohneda K, Nozawa D, Hamada H, Yoshikawa H, Ochiai N, Ohneda O (2010) Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. *Stem Cells Dev* 19:1195-1210

Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. *Blood* 108:2114-2120

Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmiopathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. *Blood* 112:295-307

Noiseux N, Gnecci M, Lopez-Illasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE (2006) Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. *Mol Ther* 14:840-850

Nystedt J, Anderson H, Tikkanen J, Pietila M, Hirvonen T, Takalo R, Heiskanen A, Satomaa T, Natunen S, Lehtonen S, Hakkarainen T, Korhonen M, Laitinen S, Valmu L, Lehenkari P (2013) Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. *Stem Cells* 31:317-326

Oskowitz A, McFerrin H, Gutschow M, Carter ML, Pochampally R (2011) Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic. *Stem Cell Res* 6:215-225

Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehniger G, Bornhauser M, Werner C (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. *Stem Cells* 22:377-384

Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. *Annu Rev Biomed Eng* 12:87-117

Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring H, Evangelista M, Hennerbichler S, Liu B, Magatti M, Mao N, Miki T, Marongiu F, Nakajima H, Nikaido T, Portmann-Lanz CB, Sankar V, Soncini M, Stadler G, Surbek D, Takahashi TA, Redl H, Sakuragawa N, Wolbank S, Zeisberger S, Zisch A, Strom SC (2008) Concise Review: Isolation and Characterization of Cells from Human Term

Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells. *Stem Cells* 26:300-311

Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Vigano L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A (2014) Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. *J Control Release* 192:262-270

Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. *J Immunol* 184:5885-5894

Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J, Noris M, Remuzzi G (2011) Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. *Clin J Am Soc Nephrol* 6:412-422

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143-147

Qu X, Liu X, Cheng K, Yang R, Zhao RC (2012) Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. *Exp Hematol* 40:761-770

Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M (2001) Repair of large bone defects with the use of autologous bone marrow stromal cells. *N Engl J Med* 344:385-386

Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E (2011) Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. *Stem Cells Dev* 20:1297-1308

Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. *Stem Cells* 26:151-162

Rani S, Ryan AE, Griffin MD, Ritter T (2015) Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. *Mol Ther* 23:812-823

Rasmusson I, Le Blanc K, Sundberg B, Ringden O (2007) Mesenchymal stem cells stimulate antibody secretion in human B cells. *Scand J Immunol* 65:336-343

References

- Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Conside RV, March KL (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. *Circulation* 109:1292-1298
- Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2:141-150
- Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM (2002) Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest* 109:337-346
- Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM (2001) Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. *Blood* 98:2615-2625
- Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnie H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation* 81:1390-1397
- Roberts CP, Murphy AA, Santanam N, Parthasarathy S (1998) Regulation of monocyte to macrophage differentiation by antigluco-corticoids and antioxidants. *Am J Obstet Gynecol* 179:354-362
- Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J (2007) Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. *J Immunol* 179:1549-1558
- Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, Roberts SJ, Luyten FP, Van Gool SW, Sampaoli M, Delforge M, Lutun A, Verfaillie CM (2011a) Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. *Stem Cells* 29:871-882
- Roobrouck VD, Vanuytsel K, Verfaillie CM (2011b) Concise Review: Culture Mediated Changes in Fate and/or Potency of Stem Cells. *Stem Cells* 29:583-589
- Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N Engl J Med* 319:1676-1680
- Ross JJ, Hong Z, Willenbring B, Zeng L, Isenberg B, Lee EH, Reyes M, Keirstead SA, Weir EK, Tranquillo RT, Verfaillie CM (2006) Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. *J Clin Invest* 116:3139-3149

Saldanha-Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas DT, Zago MA, Panepucci RA (2011) Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. *Stem Cell Res* 7:66-74

Salmikangas P, Flory E, Reinhardt J, Hinz T, Maciulaitis R (2010) Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 53:24-29

Sandor GK, Numminen J, Wolff J, Thesleff T, Miettinen A, Tuovinen VJ, Mannerstrom B, Patrikoski M, Seppanen R, Miettinen S, Rautiainen M, Ohman J (2014) Adipose stem cells used to reconstruct 13 cases with cranio-maxillofacial hard-tissue defects. *Stem Cells Transl Med* 3:530-540

Sattler C, Steinsdoerfer M, Offers M, Fischer E, Schierl R, Heseler K, Daubener W, Seissler J (2011) Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. *Cell Transplant* 20:1221-1230

Scarfi S (2014) Purinergic receptors and nucleotide processing ectoenzymes: Their roles in regulating mesenchymal stem cell functions. *World J Stem Cells* 6:153-162

Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP (2007) Stem cell transplantation: the lung barrier. *Transplant Proc* 39:573-576

Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, Smalley A, Alexander H, Walker DG, Khanna R (2014) Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. *Cancer Res* 74:3466-3476

Scott CT, Magnus D (2014) Wrongful termination: lessons from the Geron clinical trial. *Stem Cells Transl Med* 3:1398-1401

Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2009) HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. *Transplantation* 87:S62-6

Shafaei H, Esmacili A, Mardani M, Razavi S, Hashemibeni B, Nasr-Esfahani MH, Shiran MB, Esfandiari E (2011) Effects of human placental serum on proliferation and morphology of human adipose tissue-derived stem cells. *Bone Marrow Transplant* 46:1464-1471

Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE (2005) In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. *Stem Cells* 23:1357-1366

References

Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. *Transfusion* 54:1418-1437

Shetty P, Bharucha K, Tanavde V (2007) Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells. *Cell Biol Int* 31:293-298

Shi M, Liu ZW, Wang FS (2011) Immunomodulatory properties and therapeutic application of mesenchymal stem cells. *Clin Exp Immunol* 164:1-8

Sibov TT, Severino P, Marti LC, Pavon LF, Oliveira DM, Tobo PR, Campos AH, Paes AT, Amaro E, Jr, F Gamarra L, Moreira-Filho CA (2012) Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. *Cytotechnology* 64:511-521

Singer NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol* 6:457-478

Sioud M, Mobergslien A, Boudabous A, Floisand Y (2010) Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. *Scand J Immunol* 71:267-274

Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M (2006) Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. *Stem Cells* 24:462-471

Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood* 111:1327-1333

Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, Peister A, Wang MY, Prockop DJ (2003) Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. *Proc Natl Acad Sci U S A* 100:2397-2402

Squillaro T, Peluso G, Galderisi U (2016) Clinical Trials With Mesenchymal Stem Cells: An Update. *Cell Transplant* 25:829-848

Storb R (2003) Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. *Exp Hematol* 31:1-10

Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J (2012) Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. *Stem Cells Dev* 21:2724-2752

Sullivan M, Galea P, Latif S (2006) What is the appropriate oxygen tension for in vitro culture?. *Mol Hum Reprod* 12:653

Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. *Arthritis Rheum* 62:2467-2475

Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. *Haematologica* 92:1208-1215

Suszynska M, Zuba-Surma EK, Maj M, Mierzejewska K, Ratajczak J, Kucia M, Ratajczak MZ (2014) The proper criteria for identification and sorting of very small embryonic-like stem cells, and some nomenclature issues. *Stem Cells Dev* 23:702-713

Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126:663-676

Tamama K, Kawasaki H, Wells A (2010) Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. *J Biomed Biotechnol* 2010:795385

Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebe L, Societe Francaise de Greffe de Moelle et Therapie Cellulaire (2010) Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. *Blood* 115:1549-1553

Tekkatte C, Gunasingh GP, Cherian KM, Sankaranarayanan K (2011) "Humanized" stem cell culture techniques: the animal serum controversy. *Stem Cells Int* 2011:504723

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. *Science* 282:1145-1147

Timmers L, Lim SK, Arslan F, Armstrong JS, Hofer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP (2007) Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. *Stem Cell Res* 1:129-137

Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C (2007) Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. *Am J Physiol Renal Physiol* 292:F1626-35

Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C (2005) Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am J Physiol Renal Physiol* 289:F31-42

References

- Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, Capelli C, Inrona M, Remuzzi G, Benigni A (2013) Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. *Stem Cells Dev* 22:772-780
- Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L (2005) Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. *Stem Cells* 23:1105-1112
- Traggiati E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L, Martini A (2008) Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. *Stem Cells* 26:562-569
- Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH, March KL (2008) A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res* 102:77-85
- Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszyk A, Krzystyniak A, Marek N, Mysliwska J, Hellmann A (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. *Clin Immunol* 133:22-26
- Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC (2011) Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. *Blood* 117:459-469
- Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation* 75:389-397
- van den Akker F, de Jager SC, Sluijter JP (2013) Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. *Mediators Inflamm* 2013:181020
- Van Overstraeten-Schlogel N, Beguin Y, Gothot A (2006) Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. *Eur J Haematol* 76:488-493
- Vanikar AV, Trivedi HL, Feroze A, Kanodia KV, Dave SD, Shah PR (2011) Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness. *Int Urol Nephrol* 43:225-232
- Veevers-Lowe J, Ball SG, Shuttleworth A, Kielty CM (2011) Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated

activation of PDGFR-beta and potentiation of growth factor signals. *J Cell Sci* 124:1288-1300

Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, Rao DK, Das M, Jan M, Gupta PK, Totey SM (2010) Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. *Transl Res* 155:62-70

von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M (2009) Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. *Bone Marrow Transplant* 43:245-251

Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, Ho AD (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol* 33:1402-1416

Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H (2011) Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. *J Tissue Eng Regen Med* 5:146-150

Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC (2004) Mesenchymal Stem Cells in the Wharton's Jelly of the Human Umbilical Cord. *Stem Cells* 22:1330-1337

Wang X, Cheng H, Hua R, Yang J, Dai G, Zhang Z, Wang R, Qin C, An Y (2013) Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study. *Cytotherapy* 15:1549-1562

Wang Y, Sun A, Xue J, Feng C, Li J, Wu J (2009) Bone marrow derived stromal cells modified by adenovirus-mediated HIF-1alpha double mutant protect cardiac myocytes against CoCl2-induced apoptosis. *Toxicol In Vitro* 23:1069-1075

Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. *PLoS One* 5:e10088

Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP (2013) A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. *Chest* 143:1590-1598

Whiteside TL, Mandapathil M, Schuler P (2011) The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). *Curr Med Chem* 18:5217-5223

References

- Wolff J, Sandor GK, Miettinen A, Tuovinen VJ, Mannerstrom B, Patrikoski M, Miettinen S (2013) GMP-level adipose stem cells combined with computer-aided manufacturing to reconstruct mandibular ameloblastoma resection defects: Experience with three cases. *Ann Maxillofac Surg* 3:114-125
- Woodbury D, Schwarz EJ, Prockop DJ, Black IB (2000) Adult rat and human bone marrow stromal cells differentiate into neurons. *J Neurosci Res* 61:364-370
- Wu S, Ju GQ, Du T, Zhu YJ, Liu GH (2013) Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. *PLoS One* 8:e61366
- Wu Y, Chen L, Scott PG, Tredget EE (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. *Stem Cells* 25:2648-2659
- Wuchter P, Bieback K, Schrezenmeier H, Bornhauser M, Muller LP, Bonig H, Wagner W, Meisel R, Pavel P, Tonn T, Lang P, Muller I, Renner M, Malcherek G, Saffrich R, Buss EC, Horn P, Rojewski M, Schmitt A, Ho AD, Sanzenbacher R, Schmitt M (2015) Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. *Cytotherapy* 17:128-139
- Xiao Y, Peperzak V, van Rijn L, Borst J, de Bruijn JD (2010) Dexamethasone treatment during the expansion phase maintains stemness of bone marrow mesenchymal stem cells. *J Tissue Eng Regen Med* 4:374-386
- Yamanaka S, Blau HM (2010) Nuclear reprogramming to a pluripotent state by three approaches. *Nature* 465:704-712
- Yang Z, Zhang F, Ma W, Chen B, Zhou F, Xu Z, Zhang Y, Zhang D, Zhu T, Wang L, Wang H, Ding Z, Zhang Y (2010) A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-related artery. *Cardiovasc Ther* 28:380-385
- Ylostalo J, Bazhanov N, Prockop DJ (2008) Reversible commitment to differentiation by human multipotent stromal cells in single-cell-derived colonies. *Exp Hematol* 36:1390-1402
- Yoshioka S, Miura Y, Iwasa M, Fujishiro A, Yao H, Miura M, Fukuoka M, Nakagawa Y, Yokota A, Hirai H, Ichinohe T, Takaori-Kondo A, Maekawa T (2015) Isolation of mesenchymal stromal/stem cells from small-volume umbilical cord blood units that do not qualify for the banking system. *Int J Hematol* 102:218-229
- Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA (2009) Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324:797-801

Zhang B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, Shi H, Wu L, Zhu W, Qian H, Xu W (2015) HucMSC-Exosome Mediated-Wnt4 Signaling Is Required for Cutaneous Wound Healing. *Stem Cells* 33:2158-2168

Zhang L, Chan C (2010) Isolation and enrichment of rat mesenchymal stem cells (MSCs) and separation of single-colony derived MSCs. *J Vis Exp* (37). pii: 1852. doi:10.3791/1852

Zhang QZ, Su WR, Shi SH, Wilder-Smith P, Xiang AP, Wong A, Nguyen AL, Kwon CW, Le AD (2010) Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. *Stem Cells* 28:1856-1868

Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G (2013) Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. *Stem Cell Res Ther* 4:70

Zhang X, Hirai M, Cantero S, Ciubotariu R, Dobrila L, Hirsh A, Igura K, Satoh H, Yokomi I, Nishimura T, Yamaguchi S, Yoshimura K, Rubinstein P, Takahashi TA (2011) Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. *J Cell Biochem* 112:1206-1218

Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S, Geng H, Jin L, Lau GK, Wang FS (2012) Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. *J Gastroenterol Hepatol* 27 Suppl 2:112-120

Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H, Liu C, Xiao Y, Sun J, Li Y, Xiang P, Liu Q (2015) Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 21:97-104

Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW (2014) Human mesenchymal stem cell microvesicles for treatment of *Escherichia coli* endotoxin-induced acute lung injury in mice. *Stem Cells* 32:116-125

Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH (2002) Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 13:4279-4295

